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I dedicate this thesis to my parents because they have put up with me during all these years, 
and still do, and because they, after more than 60 years of marriage and through their life-
style, exemplify a lot of what this thesis is about.  
  
Live fish swim against the stream, while dead ones float with it. 
Robert Daley, 1862 
 
Whenever a theory appears to you as the only possible one, take this as a sign that you have 
neither understood the theory nor the problem which it was intended to solve. 
Karl Popper, 1972 
 
Old friends, old friends, 
Sat on their park bench like bookends … 
Time it was, and what a time it was, it was 
A time of innocence, A time of confidences 
Long ago, it must be, I have a photograph 
Preserve your memories; They're all that's left you 
Paul Simon, 1968.  
 
 
  
ABSTRACT 
With increasing life expectancies in most parts of the world, the prevalence of dementia and 
other age-related chronic diseases is growing. Several factors affect future projections and are 
discussed in this thesis, including possible limits to a continued growth of life expectancy. A 
related question is to what extent healthy ageing per se affects cognitive functions in old 
persons. Previous studies have generally exaggerated ageing effects on cognition, by applying 
study designs that did not account for common confounders, such as birth cohort differences, 
and the effects of terminal decline and subclinical dementia. In contrast to healthy ageing, 
dementia neuropathologies dramatically reduce cognitive performance, and proposed 
mechanisms behind dementia are briefly discussed with focus on Alzheimer’s disease (AD), 
on the role of genetic factors and on life course exposures. Three studies (study 1-3) 
investigated how cohabitant status and feelings of loneliness and hopelessness in midlife 
were associated with cognitive health in later life. Neurotrophic factors could potentially be 
involved in the biological mechanisms behind these and other associations between life-style 
factors and cognitive health. The fourth study aimed to explore how levels of brain-derived 
neurotrophic factor (BDNF), measured in serum, were affected by performing different 
activities; physical exercise, cognitive training, and mindfulness. 
THE FOUR STUDIES  
Study 1-3 were epidemiological association studies based on the Cardiovascular Risk Factor, 
Ageing and Dementia (CAIDE) Study, a population based cohort study on 1511 persons in 
eastern Finland, who at baseline were 50.4 years. Two re-examinations have been performed 
in the CAIDE Study, in 1998 when the participants were between 65 and 80 years, and 
between 2005-2008, averagely 25.3 years after the baseline examinations. The first two 
studies were based on the 1409 persons who fully participated in the first re-examination and 
the third study on the 1511 persons who participated in one or both re-examinations. In the 
first two studies logistic regression was the main statistical method with any cognitive 
impairment versus no cognitive impairment as outcome. In addition we performed analyses 
with mild cognitive impairment and Alzheimer’s disease as separate outcomes. In Study 1 
and 2 we also analysed how apolipoprotein epsilon 4 (ApoE4) status affected the associations 
with Alzheimer’s disease. The statistical method in Study 3 was survival model analysis 
(Kaplan-Meyer and Cox regression) and the outcome variable was dementia, without 
subtyping. We compared the results from the analysis on the 1511 participants with the 
results when we used the total sample (by including register linked data on dementia 
diagnoses). We adjusted the associations for several potential confounding variables in all 
three studies.  
In Study 4 we used 19 elderly healthy volunteers who were between 65 and 80 years (mean = 
70.8 years). They performed three different activities during 35 minutes on separate 
occasions, i.e. a within-subject cross-over experimental design where we randomized the 
order of the three conditions between the participants. We sampled blood from a suitable 
lower arm vein directly before and after each activity session and in addition at 20 and 60 
minutes after the session had ended. After the serum had been analysed for BDNF levels, we 
used repeated measures ANOVA to calculate the differences in the effect of BDNF levels 
between the three conditions. 
 
MAIN RESULTS 
We found that living alone in midlife was associated with approximately a doubled risk of 
cognitive impairment during the re-examination. Among the non-cohabitants the risk increase 
was especially high for persons who were widowed in midlife and who had continued to live 
alone until the re-examination (odds ratio (OR) 7.67, 95% confidence interval (CI) 1.6 – 
40.0). Feelings of loneliness were common both among cohabitants and non-cohabitants, but 
we found that such feelings were only associated with an increased dementia risk if these 
persons had also been living alone. Feelings of hopelessness in midlife, but not at follow-up, 
were associated with increased risk of cognitive impairment at the re-examination, especially 
of Alzheimer’s disease (OR 2.90, CI 1.4 – 5.9). When we adjusted the association from 
midlife also for depression and hopelessness at the re-examination, this association was still 
statistically significant. Participants with a diagnosis of cognitive impairment had higher 
feelings of hopelessness at the re-examination, compared to the cognitively healthy group, 
but this difference between the groups existed already when they were in midlife. When we 
stratified the participants with reference to ApoE4 status, we found that participants who 
were also ApoE4 carriers had a dramatically increased risk of Alzheimer’s disease compared 
to non-carriers without feelings of hopelessness, even after final adjustment for depression 
(OR 6.48, CI 2.4 –17.5). A similar stratification for ApoE4 status in Study 1 showed an even 
more dramatic increase in the association for persons who had lost their partner (widowed or 
divorced/separated) if they in addition were ApoE4 carriers. 
In Study 4 we found that physical exercise, but not cognitive training or mindfulness, led to a 
statistically significant increase in BDNF levels of around 25%, compared to baseline. We 
also found that the individual differences in BDNF levels after the physical exercise 
correlated with working memory performance, measured on a separate occasion. 
CONCLUSIONS 
Social and emotional factors can have long-term consequences for cognitive health in later 
life. The long follow-up time in Study 1-3 suggests that the associations we found with 
dementia could reflect a causal, rather than a prodromal, relation. As other studies have found 
a range of adverse ill health consequences from both living alone and from depressive 
feelings, a possible mechanism behind the associations we found could be related to a 
systemic biological impact, and that the specific ill health outcome could be a result of 
individual vulnerability where genetic dispositions could play an important role. This 
conclusion seems consistent with the dramatic risk increases we found for AD when ApoE4 
  
status was combined with the social factor of living alone and with the emotional dimension 
of hopelessness. At the micro level, as synaptic dysfunction and loss is characteristic of 
Alzheimer’s disease, and as BDNF has a central role for synaptogenesis, impaired BDNF 
functionality could play a role in the development of Alzheimer’s disease. More research is 
needed to further explore the role of BDNF in Alzheimer’s disease and if the disease can be 
prevented, or the disease process halted, by activities that stimulate BDNF expression in the 
brain.  
 
  
LIST OF SCIENTIFIC PAPERS 
I. Håkansson K., Rovio S., Helkala E.-L., Vilska A-R, Winblad B, Soininen 
H., Nissinen A., Mohammed A H, Kivipelto (2009). Association between 
mid-life marital status and cognitive function in later life: population based 
cohort study. British Medical Journal, 339, b2462. 
http://doi.org/10.1136/bmj.b2462 PMID: 19574312 
 
II. Håkansson K, Soininen H, Winblad B, Kivipelto M (2015) Feelings of 
Hopelessness in Midlife and Cognitive Health in Later Life: A Prospective 
Population-Based Cohort Study. PLoS ONE 10(10): e0140261. doi: 
10.1371/journal.pone.0140261 PMID: 26460971  
 
III. Håkansson K, Feng L, Soininen H, Mohammed A H, Winblad B, 
Rusanen M, Laatikainen T, Ngandu T, Kivipelto M. Living and Feeling 
Alone in Midlife - Associations with Cognitive Health in later Life. 
Manuscript. 
 
IV.  Håkansson K, Ledreux A, Daffner KR, Terjestam Y, Bergman P, Carlsson 
R, Kivipelto M, Winblad B, Granholm A-C, Mohammed A. BDNF 
Responses in Healthy Older Persons to 35 minutes of Physical Exercise, 
Cognitive Training and Mindfulness: Associations with Working Memory 
Function. J Alzheimers Dis. 2017;55(2). In press.  
  
CONTENTS 
1 Preface: about the personal journey ................................................................................ 1 
2 Introduction ...................................................................................................................... 7 
3 Cognition and cognitive health in old age ....................................................................... 9 
3.1 Demographic trends and their implications .......................................................... 9 
3.1.1 Is there an absolute limit to the human life span? .................................. 11 
3.2 Ageing and cognition .......................................................................................... 14 
3.2.1 Theories of Ageing and their Implications for Cognition ...................... 14 
3.2.2 Normal, Healthy and “Successful” Ageing – What is the 
Difference? ............................................................................................. 17 
3.2.3 What is the Isolated Effect of Ageing on Cognition? ............................ 19 
3.2.4 Conclusions ............................................................................................. 22 
3.3 Cognitive health in older age .............................................................................. 23 
3.3.1 Dementia ................................................................................................. 24 
3.3.2 Alzheimer’s Disease (AD) ..................................................................... 25 
3.3.3 The role of ApoE4 in AD ....................................................................... 26 
3.3.4 The amyloid β cascade hypothesis in AD .............................................. 27 
3.3.5 Strategies to discover new mechanisms ................................................. 28 
3.3.6 Life-course Exposures and the Brain Reserve Hypothesis .................... 29 
3.3.7 A Multitude of Life-style Associations not unique for Dementia: 
What does it mean? ................................................................................ 31 
3.4 Theoretical and methodological considerations ................................................. 33 
3.4.1 The Difference between AD Diagnosis and AD Neuropathology ........ 33 
3.4.2 The difference between Precedents and Characteristics ........................ 34 
3.4.3 Main Methodological Approaches in Dementia Research: Pros 
and Cons ................................................................................................. 34 
4 AIMS ....................................................................... Fel! Bokmärket är inte definierat. 
4.1 General aims ........................................................................................................ 41 
4.2 Specific aims of the different studies .................................................................. 41 
5 Participants and Methods ............................................................................................... 42 
5.1 Studies 1-3 ........................................................................................................... 42 
5.2 Study 4 ................................................................................................................. 45 
6 Summary of Results ....................................................................................................... 47 
6.1 Study 1 ................................................................................................................. 47 
6.2 Study 2 ................................................................................................................. 48 
6.3 Study 3 ................................................................................................................. 50 
6.4 Study 4 ................................................................................................................. 52 
7 Discussion ...................................................................................................................... 54 
7.1 Socio-emotional factors ....................................................................................... 54 
7.1.1 Cohabitants and non-cohabitants ........................................................... 54 
7.1.2 Feelings of hopelessness ......................................................................... 54 
7.1.3 Feelings of loneliness and cohabitant status .......................................... 56 
7.2 The relevance of general health mechanism for AD .......................................... 57 
7.3 BDNF: part of a specific mechanism behind alzheimer’s disease? ................... 59 
7.4 Conclusions ......................................................................................................... 60 
7.5 Future directions .................................................................................................. 60 
8 Acknowledgements ....................................................................................................... 62 
9 References ...................................................................................................................... 65 
 
  
  
LIST OF ABBREVIATIONS 
AD Alzheimer’s disease 
ApoE4 Apolipoprotein E4 allele 
BBB Blood brain barrier 
BDNF Brain-derived neurotrophic factor 
CAIDE Cardiovascular Risk Factors, Aging and Dementia  
CI Confidence interval 
CNS Central nervous system 
DMN Default Mode Network 
fMRI Functional Magnetic Resonance Imaging 
FTD Frontotemporal dementia 
HR Hazard ratio 
HR Hazard ratio 
MCI Mild cognitive impairment 
NFT Neurofibrillary tangles 
OR Odds ratio 
SAGE Successful Ageing and Enrichment  
VAD Vascular dementia 
  
 

  1 
1 PREFACE: ABOUT THE PERSONAL JOURNEY 
A doctoral thesis is the outcome of an education, a manifestation of skills, and also, in the 
ideal case, a significant contribution to knowledge. On another level it also represents a 
personal journey. For me this journey has been an exciting adventure and I would like to start 
with this aspect of my thesis. This is the parallel personal and subjective version of this thesis, 
a part that is neither common, mandatory or needed in a doctoral thesis. It is written as a more 
accessible version especially for readers who are not scientists and for those who might have 
an interest in the more personal side of the research process. If you don´t belong to any of 
these categories, you can easily skip this part and go directly to Chapter 2.  
In 1968 Simon & Garfunkel, one of my favourite groups at the time, released a new album 
called “Bookends”. The lyrics were all about old people and their stories. When in high 
school we were allowed to freely chose a topic and conduct a study around that topic, my 
decision was greatly inspired by this album. I still remember many of the old persons I met, 
their life stories what they told me about getting old.  
A few years later I worked at a hospital in Kristianstad for severely demented people. After 
more than 40 years I still have vivid memories of some of the very demented patients I met 
there. I imagine these experiences both have been important seeds to this thesis, and I also 
think that personal experiences of this kind has an important complementary role to what you 
learn from books and articles about ageing and dementia. These and similar experiences have 
kept reminding me that there are real people behind all the numbers and calculations you will 
encounter in other parts of this thesis. 
In one way, to write a thesis about late-life cognitive health thus seemed like closing a circle 
by returning to experiences and questions I had asked myself when I was very young.  
One day my colleague at the Linnaeus University, Abdul Mohammed, invited me to visit his 
department at Karolinska Institutet, where he also worked. At the visit to the department of 
Neurobiology, Care Sciences and Society I was fortunate to have a meeting scheduled with 
Bengt Winblad and Miia Kivipelto, who gave me access to the unique CAIDE1 database 
from Finland, a population-based registry with baseline data from the seventies. For a person 
with a psychological background like myself, the large amount of unexplored information on 
social and psychological factors in this database was like a treasure. As I knew that other 
studies had found intellectual and social stimulation to be associated with better cognitive 
health, I made some initial calculations to compare people who had been married or living 
with someone in midlife with persons who had not, a variable that in medical research is 
usually considered as a possible confounder and something to adjust for while looking for 
other things. But like many others, I had from personal experience made the conclusion that 
living with someone is not only a social project, but also a cognitively challenging one. When 
                                                
1 CAIDE stands for Cardiovascular Risk Factors, Aging and Dementia 
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the number (the “odds ratio”) appeared on my computer screen, indicating a seven-fold risk 
increase for widowed persons in this population, it was a flash bulb moment I will never 
forget. First I did not believe the numbers I got and thought I must have done a mistake in the 
calculation. After several double checks and recalculations I was finally convinced. I then 
subdivided the participants into carriers and non-carriers of the APOE42 allele, and the risk 
rocketed for those who both had been living alone after losing their partners in midlife and 
who in addition carried this allele. The odds ratios I had found for Alzheimer’s disease, over 
20 for the combined risk, were higher than I had seen in the literature for any other risk 
factor. 
When I brought my results on the train to Stockholm I was quite nervous that I had 
“discovered” something others had already observed in this database before me. This was 
however not the case and everybody I talked to was happy and enthusiastic over the findings. 
I have often thought that this kind of reaction, the readiness to accept and reward new ideas, 
findings and accomplishments, could be one of the success factors for this institute. At 
Karolinska it has for me been easy to feel like a member in a soccer team and when you 
score, the team scores, and everybody is happy. (No, I am not naïve about competition and 
envy in the academic world at large, but this kind of attitude has been the rule rather than the 
exception in the groups I have worked with at Karolinska.) 
To find an association of this kind is one thing. But trying to figure out what it means, and 
how to test such ideas, that is where the real fun starts. What was it about living with 
someone that was so favourable? If it was the cognitive stimulation in a close relation that 
mattered mostly, why were the singles so much better off than the divorced and especially the 
widowed? In contrast to the singles, at least they had had a portion of the possible health 
benefits from a cognitively challenging partner relation. Was it rather about the emotional 
consequences of losing a partner, especially if the partner dies from you, like feelings of 
hopelessness and loneliness? On the other hand, even if you live with someone, would not the 
quality of the relation matter more than living with someone per se? E.g. how many people 
feel even more alone from living with someone if the relation is not working? Trained in the 
experimental tradition, I also had permanent doubts about the validity of epidemiological 
association findings where a lot of possible confounders can not be fully controlled and 
where you can not even be sure about the direction of causality, if any, between the factor of 
interest and an “outcome”. Especially in the case of dementia, with such a long subclinical 
disease phase, these doubts kept worrying me. These questions about the underlying 
mechanisms and the methodological concerns increased my curiosity and guided the studies 
that followed, most of them included in this thesis. 
One of the issues that troubled me the most was the issue of reverse causation. I realized how 
lucky I was to work with a database with a follow-up time of over 20 years and with 
                                                
2 APOE4 is an allele that is known to increase the risk for Alzheimer’s disease. Its prevalence varies 
largely across populations and around 20% carry this allele in Northern Europe [1]. 
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participants only around 50 at baseline. Compared to most other studies of this kind, these 
features reduced the risk that even a subclinical dementia disease could have affected the 
variable of interest, the “predictor” variable, already at baseline. Another concern was the 
consequences of self-selected, rather than randomized, groups, for example persons who 
decide to marry versus the ones that don´t – or persons who embark on a long education 
versus people that don´t. How do I know that these differences are not also related to other 
factors, such as personality, intelligence or childhood experiences, factors that could not be 
included in the statistical adjustments, but could still be the ones that really mattered? In the 
first study I had been lucky also in that regard as the main difference was between two groups 
of persons who both initially married someone, and thus could be assumed similar also in 
such other respects.  
It is probably true that both of these methodological concerns; the risk of reverse causation 
and the risk of uncontrolled confounders behind an association, have stamped the way I have 
approached the different research questions, and in the end even made me include a well-
controlled experimental study to complement the epidemiological association study approach. 
Especially for depression, I quickly realized that reverse causation was a hot topic – are 
depressive feelings a true risk factor or is it an early consequence of even a sub-clinical 
dementia disease process? With the data on hopelessness in the CAIDE database, it was 
possible to show that persons with a dementia diagnosis in later life had higher levels of these 
feelings shortly prior to the diagnosis. But it was also possible to go back in time and show 
that the same difference existed decades before, already in midlife. An elegant and 
theoretically significant demonstration of depressive feelings as causal, rather than 
prodromal, I thought. Clearly, these results were in conflict with what many researchers 
thought to be the case – and perhaps less “spectacular”, compared to the first study on marital 
status. For whatever reason, it proved difficult to get the article published in the more 
prestigious journals. I concluded that the quick and successful BMJ publication of the first 
study had spoiled me, and perhaps also given unrealistic expectations to others that my thesis 
would be a quick affair. Yes, it was very close a couple of times, but in the end I had to climb 
down the impact factor ladder a bit to finally get the second article published. At least it 
taught me a lot about publication policies and review processes in different journals. It made 
me realize that scientific journals and their editors are operating on a market and need articles 
that can give them public recognition and attention. That people who continue to live alone 
after a divorce or the death of a partner increase their dementia risk, is by these standards 
perhaps a more “spectacular” result than levels of hopelessness at different time points for 
persons that will, or will not, have a dementia diagnosis in later life. But theoretically, to 
understand disease mechanisms, was not the latter result of greater significance?  
The idea to include an experimental study was welcomed by my supervisors and beneficial to 
develop my understanding of the relative merits of the two methodological approaches. 
Trained in the experimental tradition as a psychologist, I was happy to finally do a “clean” 
experimental study with perfect control of both reverse causation and confounding factors. 
But it soon became evident to me that each of the two approaches has to make different kinds 
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of sacrifices to address key issues in dementia research and that one of the methodological 
approaches is not inherently superior to the other, in spite of a present strong preference 
among journals for only one of these approaches. In this thesis I have devoted a special 
chapter to compare the pros and cons of the different methodological approaches I have used, 
and in what way one can complement the other.  
Epidemiological studies can at best identify factors, many of which can be modified through 
life style changes, that are beneficial for healthy cognitive ageing or, stated the other way 
around, are somehow involved in the causal chain leading to a dementia diagnosis. Such 
knowledge is undoubtedly important for health professionals to design preventive measures 
for people at risk and give good health advice, for public health information and as a guide 
for anyone to modify your own life style in a more healthy direction.  
The other benefit of such knowledge is to serve as a clue to find the underlying biological 
mechanisms of the disease. In that respect, to establish an association with e.g. physical 
activity, a certain diet or feelings of loneliness at one point in time, and a dementia diagnosis 
decades later, could be regarded as rather trivial in itself. The interesting question is why. 
Already when I had the first result I asked myself how losing a partner could trigger 
biological processes that could lead to a dementia disease decades later. In my mind, one key 
to answer this question is the multitude of other factors that show a similar association. 
Another observation is that these factors are usually not uniquely associated with one 
dementia disease, but to many, and in addition to other diseases as well. In what direction do 
these clues lead when we think of biological mechanisms behind e.g. Alzheimer’s disease? I 
do realize that on one level every disease is very specific, but does it mean that non-specific 
disease factors are less important to consider? If we only focus on single diseases and single 
risk factors for that specific disease, could it sometimes make us blind to see what lies in front 
of us? One of many examples is the focus on beta amyloids in Alzheimer research. While 
epidemiological associations need to be related to the chain of events that later follow, would 
our understanding not in a corresponding way benefit from tracing the events that preceded 
the occurrence of this disease-related peptide? If the accumulation of amyloid plaques (or 
changes in the tau protein) is related to Alzheimer’s disease, and if a much earlier emotional 
trauma also is, then somehow these more long term and short term antecedents of the disease 
need to be bridged. How does the chain of events look that can link them all together?  
This means that, even if my background is in Psychology, I see the need to relate e.g. 
experiences and emotions with biology, which in turn means that I think that people with 
expertise in these different areas need to work and think together to solve this puzzle, a belief 
that is certainly not unique. Already in the first study, the results gave me a strong indication 
that social and emotional factors alone can´t give the whole story; when I combined the 
experience of living alone, especially after having lost a partner, with a genetic factor, this 
addition of the genetic component changed the picture dramatically. At the same time, if I 
only looked at the genetic risk, while controlling for other factors, the genetic risk increase 
per se was quite modest. My conclusion was that the event I had been looking at probably 
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constituted a general long-term health risk, but for those with the ApoE4 allele, Alzheimer’s 
disease was a relatively more probable ill health outcome. 
Related to the difference between establishing associations and identifying mechanisms is the 
distinction between postponing and preventing the disease. As long as the time point and the 
very fist stages of the disease are unknown, this distinction could be regarded as highly 
theoretical and abstract, perhaps of little use, even. Still I think it is a distinction that is crucial 
to make, but that few people seem very concerned about. As a result, it is common with 
sweeping and unfounded statements as to when the disease starts where risk factors are often 
confused with the disease itself. One example is if a difference in intelligence can be 
established already in childhood between persons with a higher or lower risk to be diagnosed 
with the disease when they get old. Does this mean that the disease started already in 
childhood? Of course not! It probably only means that once the disease has started, persons 
with a lower intelligence, because of lower cognitive reserve, will reach the level of cognitive 
functioning when the diagnosis can be made at an earlier point in time. Calculated on a group 
level, it will still seem as if a high intelligence “protects” against the disease, as fewer persons 
of a certain age will have a dementia diagnosis if they had a higher intelligence to start with. 
For the same reason, accumulating evidence now tells us that education does not prevent 
from dementia. Instead a higher education will mean that, due to better cognitive functioning, 
it will take longer time before a person with an underlying dementia disease will have 
reached the clinical criteria, in terms of cognitive functioning. At the same time, it is well 
possible that cognitive training can strengthen brain functioning in early phases of the disease 
to postpone the disease from a clinical point of view. In other words, education and cognitive 
training can probably postpone the disease in clinical terms, but probably not prevent or even 
delay the neuropathological initiation of the same disease process. While both of these aims 
are important, i.e. interventions to delay the clinical debut and measures to prevent the 
disease process to start, clearly the latter should be the holy grail of dementia research. The 
reason is simple: As far as we know, once a dementia disease like Alzheimer’s disease, has 
started, it is an irreversible process that eventually, if the persons lives long enough, will 
literally ruin the persons life and brain, and also heavily affect the lives of persons around 
diseased person. 
This debate refers to the basic question of what dementia is. Is it a clinical diagnosis of a 
disease or is it the neuropathological process that eventually will manifest in the clinical 
symptoms that fulfil criteria for such a diagnosis? A clinician with a more pragmatic attitude 
will probably vote for the first, while a neuroscience researcher or a pathologist will more 
probably lean towards the latter definition. At least it would make me happy to think that the 
emotional and social events I have studied have more to do with mechanisms that can trigger 
the disease process to start, rather than modifying the trajectory of a disease that is already in 
progress.  
Many other thoughts and ideas have developed as I have been working with this project, but I 
hope this simple introduction can convey some of the fascination and curiosity that has 
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characterized the intellectual adventure and the personal journey behind. I also hope it can 
stimulate the appetite in readers without much experience of research to eventually make a 
similar journey.
  7 
2 INTRODUCTION 
This thesis deals with possible long term effects on cognitive health from living alone, the 
trauma of losing a partner, feelings of hopelessness and loneliness, and in addition the 
possible implication of brain-derived neurotrophic factor (BDNF) in the biological 
mechanisms behind these associations and for cognitive health in general. As the original 
articles are included at the end of the thesis, the main purpose of the text that follows is to 
expand, complement and to put the included studies into a wider theoretical and 
methodological context, rather than repeating what was already written in the articles. Three 
of these studies describe and discuss long-term associations by using an epidemiological 
study approach, while the fourth experimental study has a more direct focus on biological 
mechanisms. One objective of this thesis is therefore also to bridge between these two 
methodological approaches to illustrate their complementary value. The focus in three of the 
articles is on risk factors for cognitive impairment, while the fourth has a focus on healthy 
cognition. In summary, this means that this thesis can be seen as a bold attempt to integrate 
the relevance of socio-emotional factors with biological mechanisms and also to apply the 
two main methodological approaches, epidemiological association studies and experimental 
intervention studies, in research on cognitive ageing.  
After a short overview of demographic trends, their driving forces and implications for 
dementia prevalence, I will in the following discuss the concepts of ageing and cognitive 
ageing, the impact of ageing on cognition and possible mechanisms behind trajectories of 
cognitive ageing, dementia with a focus on Alzheimer’s disease and possible underlying 
mechanisms, the relevance of life-course exposures for cognitive health and the possible role 
of neurotrophins, including brain-derived neurotrophic factor (BDNF), for healthy brain 
functioning. The pros and cons of the main methodological approaches in dementia research 
are also introduced before the aims and the different studies in this thesis are introduced. 
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3 COGNITION AND COGNITIVE HEALTH IN OLD AGE 
3.1 DEMOGRAPHIC TRENDS AND THEIR IMPLICATIONS 
As a result of increasing life expectancies, and in spite of a progressive decline in fertility 
rate, the global population is growing, and especially its proportion of old persons. The 
continued development of life expectancies is of critical importance for policy makers and 
politicians for several reasons: for adaptation of pension and taxation systems, for adequate 
allocation of health care resources, and for strategic research investments. If we can expect a 
continued increase in human life expectancies, it will become increasingly important to 
prevent, cure and delay age-related diseases, including dementia, both from a societal and 
economic perspective and from a welfare perspective. Two factors seem especially important 
to estimate what we can expect in this regard: the driving forces behind the on-going increase 
in global life expectancies and whether the human life span has a biological limit or not. In 
this chapter I therefore will shortly review hypotheses and empirical evidence related to these 
two issues. 
During the last half century the fertility rate dropped from 5.2 to 2.7, but with a compensating 
parallel decrease in child and maternal mortality; between 1970 and 2010 child mortality 
dropped by around 50% [2] and maternal mortality has dropped annually by 1.5% since 1980 
[3]. A related global trend is that more people reach a mature age and in addition have a 
higher remaining life expectancy thereafter [4]. The proportion of persons above 65 in the 
world was 6.9% in 2000 and is expected to grow to 16.3% in 2050, a proportion that has 
already been surpassed by countries such as Japan (24.8%), Italy (20.8%), Sweden (20,5%) 
(Fig 1), and Germany (20.9%) [5]. An even faster relative growth is taking place in the 85+ 
segment of the world population [6]. To exemplify, data from Human Mortality Data base [7] 
show that the 85+ proportion of the Swedish population was constantly below 0.5% during 
200 years from 1750 until 1950, but has since then grown steadily from around 0.55% in the 
fifties to 2.65% at present, i.e. an approximate five-fold increase during the last sixty years 
(see Fig 1).  
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Figure 1. The proportions of persons above 65 and above 85 years in Sweden between 1751 
and 2015.  
Values retrieved from Human Mortality Database [7]  
This combined trend of decreasing birth rates and increasing longevity can be seen in all parts 
of the world, but has progressed farther in more developed regions. As a result, global life 
expectancy at birth has increased by over twenty years during the last six decades, from 46.8 
years in 1950 to 70.5 years today - with a prognosis to approach 75 in 2050 [4], a life 
expectancy already surpassed in countries like Japan, Germany, Sweden, and Italy [5]. In 
Sweden, a country with the one of the best historic demographic registers in the world, the 
steady increase in life expectancy over three centuries, from below 40 in 1751 to over 80 
years today, is illustrated in Figure 2. 
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Figure 2. Development of Life expectancy in Sweden between 1751 and 2014 
Values derived from Human Mortality Database [7] 
3.1.1 Is there an absolute limit to the human life span? 
It is easy to doubt that this trend can continue forever and that we at some point will have 
reached a limit of continued increases in life expectancy. Many attempts have been made to 
determine such a limit, starting with Dublin’s in 1928 [8]. His calculations resulted in an 
estimation of 64.75 years [8], an estimation that was soon proven inadequately pessimistic. 
According to Oeppen and Vaupel [8] it has only taken five years on average from publication 
to break the fourteen suggested life expectancy limits that were presented between 1928 and 
1990, including the 85 year limit presented in 1990 by Olshansky et al. [9]. If todays sceptics 
are equally wrong as those of the past, estimations have been made that a majority of the 
children born today in western Europe, the US, and Japan will experience their 100th birthday 
[6].  
In contrast to life expectancies of populations, the maximum life spans of single individuals 
have increased to a much less extent. As exemplified by Swedish data, while life expectancy 
doubled during the last two centuries, there are repeated records from at least 1860 and 
onwards of many single individuals who lived more than 100 years [10]. Does this dramatic 
difference between the development of life expectancy at the population level and the very 
small increase in maximum life spans at the individual level indicate that there is an absolute 
limit to a human life span – and thus a limit to continued increases in human life expectancy? 
Some argue it does, and that this absolute limit is approximately 120 years [11,12].  
A relevant distinction in this context is that between observed maximum life span and a 
theoretical “absolute” one [13]. When Fries wrote his classical paper in 1980, he stated, as 
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evidence for a fixed limit to the human life span that “…adequate data on the number of 
centenarians have been available in England since 1837; over this time, despite a great 
change in average life expectancy, there has been no detectable change in the number of 
people living longer than 100 years or in the maximum age of persons dying in a given year” 
(p 131) [14]. This argument does not apply today. The proportion of centenarians in the 
Swedish population is more than thirty-fold of the proportion that existed in the middle of the 
previous century. In line with Fries’ argument, there were indeed repeated single instances of 
persons that reached the even higher age of 105 during the preceding centuries, but this 
number has increased dramatically during the last few decades (see Fig 3). If we choose the 
even more extreme age of 110 years, there were no records of such an old person in Sweden 
between 1751 and 1980, but since then several Swedish inhabitants have reached this age. 
Even if this proves that Fries was wrong about the premises of his argument, does it prove he 
was also wrong in his conclusion? Not necessarily. If we take the distinction between 
observed and absolute life span seriously, the problem with Fries’ argument is instead its 
logic. An alternative interpretation is that the rapid growth of super-centenarians in Sweden 
(see Fig 3) could mean that observed maximum life spans is approaching the proposed 
absolute limit, possibly as a result of reducing “avoidable mortality” through more healthy 
life styles and improved health care [15].  
 
Figure 3. Number of persons 105 years or older in the Swedish population from 1751 to 
2015.  
Values derived from Human Mortality Database [7] 
An expected consequence of the suggested 122 year limit to a human life span [11,12] should 
be a shift towards a more quadratic survival curve as more and more people enter into very 
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old age. If no compression of mortality can be demonstrated with prolonged life expectancies, 
this would seem to constitute a valid argument against the existence of an absolute life span 
limit for humans. However, in a recent and thorough analysis, Mathers et al [15] found no 
evidence for compression of mortality. There is even strong evidence to the contrary, a 
deceleration of mortality with very high age [16]. The meaning of this phenomenon is, 
perhaps surprisingly, that the risk of dying within the following year is higher for a single 
person of e.g. 85 years than for a person who has survived until e.g.105.  
Related to compression of mortality is the “compression of morbidity” hypothesis {[14], 
based on a similar assumption of a biological human life span limit. According to this 
influential idea, improving life conditions will postpone the incidence of chronic diseases and 
hospitalisation until later in life. The evidence for compression of morbidity seemed 
convincing when first presented and may adequately have described the development during 
a large part of the previous century [14]. More recent evidence however suggests that people 
live longer today due to better survival in spite of chronic diseases [17] - or even in spite of 
expanded, rather than compressed, morbidity [18]. Thus, better health in old age does not 
seem as a valid explanation to account for increased life expectancies across the world. More 
importantly, for those who live until old age, modern medicine has become increasingly 
efficient in helping old persons survive many chronic conditions that previously were fatal.  
In summary, life expectancies continue to increase across the world, and in Sweden, a 
country with especially good historic demographic records, this trend can be observed as 
accelerating up to now (Fig 2). It may seem natural to assume the existence of a biological 
and unsurpassable limit to a human life span, but some empirical data, especially the failure 
to empirically demonstrate compression of mortality, does not support such an assumption. 
As observed maximum life spans of single individuals have not increased over time at a rate 
near that of life expectancies in populations, the major driving force behind the on-going 
increase in life expectancy is most likely due to life style changes, such as the recent decrease 
in smoking in high-income countries [15], and progress in medical care, rather than a 
tendency for the oldest old to become even older before they die. On the other hand, if this 
scenario does not produce compression of mortality, which it should in the case of an 
absolute limit to human life span, it could either mean that we are not close to this limit yet – 
or that it does not exist.  
For most of us, the main objective may however not be to live as long as possible, but to live 
well and to have our mental powers well preserved when we get old. What do we know about 
the prospects for this to happen? 
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3.2 AGEING AND COGNITION 
The purpose of this chapter is to give a framework to the main research questions of this 
thesis and it is beyond the scope of this dissertation to cover all aspects and details of 
cognitive ageing, including distinctions between cognitive domains and their neural 
correlates. Instead the focus will be on general and methodological issues related to ageing 
and cognition.  
3.2.1 Theories of Ageing and their Implications for Cognition  
Many studies have described how trajectories of cognitive function decrease by age and 
given the impression that cognitive decline is a natural consequence of getting old. Although 
this to some extent is probably true, more recent evidence based on more adequate study 
designs illustrate that many of the previous claims have been overly categorical and 
pessimistic in this regard [19]. One of the key features in the association between aging and 
cognition is the amount of individual differences in both cognitive functioning at a certain 
age and the different trajectories of cognitive functioning with increasing age, including 
persons whose cognitive functioning seem more or less unaffected by advancing age [20]. 
3.2.1.1 Cognitive ageing as a function of a general ageing mechanism 
One reason for cognition to actually suffer with ageing could potentially be related to any of 
the mechanisms of the ageing process itself. Over 300 theories of ageing have been proposed 
[21], but there is still no common agreement what constitutes a basic mechanism of ageing. 
In the following I will only touch upon a few of them, and try to relate them to one another.  
A common view is based on the fact that as long as we live, cells divide and die, at different 
rates in different parts of the body. When a cell is about to copy itself, small errors may occur 
to make the copy less perfect than its mother cell, an imperfection that then will be 
reproduced in the coming generations of cells. One example of accumulated imperfections is 
the suggested progressive shortening of chromosome telomere length with each cell division 
[22]. Telomeres function as “caps” at the end of chromosomes to keep them intact and when 
telomeres become too short to perform this task, the functioning of the hosting cell will 
eventually become fatally disrupted. According to some evidence, telomere length is however 
not the only thing that matters for telomeres to perform their task; even very short telomeres 
can be efficient when they bind to a certain protein, the TRF2 [23], a protein that 
paradoxically has been reported to both contributes to telomere shortening and increasing 
telomere efficiency - but that also requires cell divisions to become expressed [23]. Although 
several, but not all[24], studies report a correlation between telomere length and biological 
age, several longitudinal studies have failed to establish telomere length as a predictor of 
morbidity and mortality [25] [26]. Although some studies indicate that telomere length has 
relevance for cognitive ageing[27], others failed to find support for an association [28]. For 
age-related neuropathologies, such as Alzheimer’s disease, the evidence for telomere 
shortening as mechanistically involved is also mixed [29]. 
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As cell divisions occur at a certain rate through our lives, and if cell divisions imply 
accumulation of age-relevant disturbances in cell function, such a mechanism would mean 
that life is ticking towards a certain end when vital body functions can no longer be upheld. 
Such a “clock mechanism” seems highly consistent with the idea of a maximum human life 
span, as does the epigenetic clock theory of DNA methylations, suggested as a parallel clock 
to that of telomere shortening [30]. This theory has two aspects of relevance for ageing 
theory: that the rate of methylations is reduced with higher age and in addition that the basic 
individual rate of methylation predicts longevity and age-related diseases [31], including 
Alzheimer’s disease [32]. Evidence from this research field indicates that centenarians 
typically have a lower methylation rate than expected from their chronological age, indicating 
a lower basic rate of methylation. One important difference between the telomere length and 
the methylation approaches is this emphasis in theories of methylation on individual 
differences. In common language, this difference means that clocks are ticking at different 
rates in different individuals, thereby introducing also a predicted difference in maximum 
individual life spans. The similarity in relation to ageing theory is on the other hand that they 
both assume that ageing is a pre-programmed process that imposes a definite life span limit.  
Other theories state that ageing is the result of accumulated stochastic events, rather than a 
pre-programmed mechanism, such as DNA mutations from radiation or toxic exposures, 
events that could also lead to deficiencies in cell reproduction or cause other deviations from 
optimal functioning at the cell level. Related to this is the theory that repair mechanisms to 
resist accumulation of unfortunate events may also differ between individuals [33]. If these 
theories are correct, the length a human life span will to a greater extent be a consequence of 
luck in combination with accumulated exposures and efficiency of repair mechanisms, and 
thus partly a consequence of individual choices, rather than deterministically fixed by some 
kind of biological ageing program. This view would then be consistent with the view that a 
human life span does not have an absolute limit, common to all humans, and that longevity is 
better explained by a probabilistic function. 
That different theories exist does not necessarily mean that they exclude each other; several 
of the theories I have shortly mentioned could have relevance and contribute in a 
complementary way. However, one problem for most of these ageing theories to also account 
for cognitive ageing is their reliance on cell divisions, a rare event in the organ that 
constitutes the biological basis for cognitive processes. According to present knowledge, only 
one part of the brain, the hippocampus, manifest cell division and neurogenesis. One reason 
for the brain being an exception in this regard could be evolutionary pressure to maintain 
brain cells and brain circuits over the life span due to their critical role for memory and 
identity, and thereby for survival[34]. This should mean that all ageing theories related to 
accumulated imperfections through cell divisions, whatever their causes and effects, are less 
relevant to explain brain ageing and cognitive ageing, in contrast to ageing processes in the 
rest of the body.  
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3.2.1.2 Cognitive ageing as a function brain ageing 
Although cell division is such a rare phenomenon in the brain, there are other possibilities 
that ageing per se could account for cognitive decline. To exemplify, one theory suggests that 
brain cells could become less efficient with age through pre-programmed down regulation, 
leading to cognitive decline and eventually also neurodegeneration [35]. The reason for this, 
according to this theory, is related to the evolutionary advantage of saving energy. The 
brain is by far the body organ with the highest energy consumption in relation to its mass and 
economization is a pervasive principle in the brain at all levels, including re-uptake 
(recirculation) of transmittor substances at synapses and top-down processing in perception 
and neurological functioning [36]. According to this theory, with higher age the individual 
has acquired knowledge and experiences to a degree where further learning is becoming less 
and less critical for survival [35]. To make brain functioning less demanding, energy-
consuming processes related to learning, such as synaptogenesis and formation of new neural 
networks, are therefore down regulated. Of possible relevance for evaluation for this 
hypothesis is the progressive reduction in metabolism with age, [37] which could mean that 
sustaining life with minimal energy expenditure may have a general evolutionary advantage. 
Evidence that DNA methylation decreases with age, signalling reduced epigenetic 
modifications in response to experience [36], also seems in line with this evolution-based 
theory. As always, evolutionary theories are difficult to test and it remains to be seen if a 
neuron “down regulation-by-age” program can be identified to account for cognitive decline 
in older age.  
Another potential ageing mechanism that directly could affect the brain, also suggested by 
Harman [11], to account for an absolute limit in the human life span of 122 years, is the 
accumulation of free radicals with metabolism [11]. Especially the mitochondria, the power 
house of both nerve cells and other cells, should be especially susceptible to DNA and cell 
membrane damage caused by oxidative stress [38]. That metabolism itself could drive the 
ageing process also seems consistent with the anti-ageing effects of calorie restriction [39], 
and of anti-oxidants, both through an efficient endogenous antioxidant defence system [40], 
and probably also through intake of natural antioxidants in diet [41], but not through anti-
oxidant supplements [42].  
3.2.1.3 Cognitive ageing as a function of age-related deficiencies in brain-supporting 
systems 
Another way to understand why ageing could affect cognition and the brain, in spite of neural 
cell divisions being non-typical, and as an alternative to theories specific to brain ageing, is to 
realise that the brain does not exist in isolation; brain processes are highly dependent on other 
organs and their functioning, organs that do not belong to the same exception as the brain in 
terms of cell division and accumulating cell copy imperfections with age. The cardiovascular 
system is perhaps the best example, of primary importance to provide oxygen, nutrition and 
vitamins to brain cells. With time there is also a tendency for blood vessels to become less 
efficient in their ability to nourish brain cells for other reasons than mechanisms related to 
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ageing per se, such as vascular damages from high blood pressure, diabetes, inappropriate 
diet, smoking and a host of other adverse life style factors. As the brain is so critically 
dependent on a continuous blood supply, both age-related and life-style related 
cardiovascular deficiencies have direct consequences for how well the brain can function and 
for survival of neurons [43]. An obvious case is stroke that could kill billions of neurons, but 
more and more attention has been given to “mini-infarcts”, events in the brain that we 
normally do not even notice. A related event is a temporary reduction in blood supply, a 
transient ischemic attacks (TIA), usually caused by a clot that temporarily blocks the blood 
supply in a fine vessel, an event that is also associated with increased risk of stroke [44]. As a 
neuron in normal temperature can only survive around eight minutes without oxygen, such 
events present an obvious risk of neural cell death or at least impaired functioning due to lack 
of oxygen. When such events accumulate, the functioning of the brain as a whole will 
naturally suffer and could in the end affect cognitive functions to a degree that justifies a 
dementia diagnosis. As we shall see, a deficient cardiovascular system may not only affect 
the risk of vascular dementia, but, through mechanisms largely unknown, also the risk of 
dementia from Alzheimer’s disease[43]. 
3.2.1.4 Individual differences in cognitive ageing as a function of accumulated exposures 
As exposure effects accumulate, including mutations, errors in the cell copying machinery, 
and experiences with epigenetic consequences, the room for variation between individuals 
increases. We are all different in many regards; in personality, intelligence, body 
composition, physical constitution and much more. A universal feature seems to be that such 
individual differences get accentuated with age. Even homozygotic twins become 
progressively more different with advanced age, including in their DNA methylation marks, 
an observation commonly explained as “epigenetic drift”, i.e. an effect of accumulating inter-
individual differences in epigenetic influences on the genome [45].  
3.2.2 Normal, Healthy and “Successful” Ageing – What is the Difference? 
One question in relation to this variation is what constitutes “normal ageing” or “healthy 
ageing” - and the utility of these concepts. Obviously different old persons will manifest a 
continuum of better or worse functioning, including at the cognitive level, for already 
mentioned reasons. The discussion concerning normal or healthy ageing and cognition 
resembles a parallel discussion concerning the health concept itself. Is health synonymous 
with absence of diseases, as diagnosed through certain agreed-upon criteria, or is it something 
more? According to WHO, health should be defined as “a state of complete physical, mental, 
and social well-being and not merely the absence of disease or infirmity” [46]. A typical 
argument against applying this definition to ageing would be that it transforms healthy ageing 
to an extremely rare, almost non-existent entity. Already after 60 years of age, a majority of 
persons have at least one chronic disease, and the corresponding prevalence among 
octogenarians is over 80% [47].  
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Inherent in this statistical objection against the concept of healthy ageing as an absolute and 
ideal entity, is the preference for a more relative and “realistic” definition, i.e. that normal and 
healthy ageing is the level of functioning that is common or typical in a certain age group, 
sometimes called “normative ageing”[48]. The problem with such a definition is that if most 
persons at an advanced age have diseases, as we have seen that they indeed have [47], they 
would still be defined as belonging to the category of “healthy” or normal ageing. As disease 
by its definition is opposite to health, a valid argument could be that this represents a misuse 
of language. The relative definition has also been criticised for precisely its relative nature: 
whether someone is ageing in a normal/healthy fashion or not will depend on the level of 
health of everybody else in the same age category - and how the health of others may change. 
 One way to approach the concepts of normality and health in relation to ageing could be to 
distinguish between them, and at least avoid to define healthy ageing as inclusive of persons 
with diseases. But, to complicate matters even more, even the distinction between disease and 
non-disease is debatable and relative, as illustrated by the recent concept of sub-optimal 
health [49]. Persons with suboptimal health do not fulfil criteria for illness diagnoses, but still 
have impaired function due to suboptimal functioning on various levels. Exclusion of persons 
also with health impairments that do not qualify for illness diagnoses, would bring us back to 
a definition of healthy ageing analogous to the WHO health definition, i.e. ageing along with 
“complete physical, mental and social well-being”. With this proposed distinction, normal 
ageing would, in contrast to the ideal of healthy ageing, or “successful ageing”, be ageing that 
is typical for the birth cohort we belong to, apt to change with later cohorts. An obvious 
objective for research and the medical profession would then be to contribute to the 
transformation of normal ageing in the direction towards healthy ageing.  
Although the concepts of healthy, successful, normal and normative ageing are extensively 
used and discussed, a possible alternative conclusion from the above could be that both these 
concepts are arbitrary and unnecessary and may be more about the human need to classify 
and simplify phenomena that naturally vary, than about their usefulness.  
The complications to define healthy ageing are paralleled in the attempts to define healthy 
cognitive ageing[48]. If we apply the suggested definitions of healthy and normal ageing to 
cognitive functioning, healthy cognitive ageing would be the level of cognition that is optimal 
for a certain age cohort, whereas normal cognitive ageing would be a level of cognition that is 
most commonly found in the same age group. Besides the statistical argument, a problem 
with the concept healthy cognitive ageing is establishing the biological limits for optimal 
cognition for any single person. This can be exemplified by the concept of “cognitive 
decline”, commonly used in ageing research. In both clinical and research settings, cognitive 
decline is often determined by measuring the level of cognitive performance. The most 
commonly used screening tool to detect cognitive decline is the Minimental Scale 
Examination (MMSE) [50] and a common threshold value is a performance score of 24 or 
below on that test. But, as critics have pointed out, the term decline denotes a change of 
performance, not a level of performance. Optimal functioning for a well-educated and 
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intelligent person would most probably correspond to a score of 30 on this test, while optimal 
functioning for another person could be considerably lower.  If the first of these persons 
would perform at a level of 26, this could constitute a serious level of cognitive decline, while 
it might not for the second person. The fact that MMSE can be considered as a crude measure 
of cognitive performance does not change this argument. Even with the most sophisticated 
neuropsychological battery, we need at least two measure points in order to say anything 
about either cognitive decline or optimal cognitive performance for any person.  
The fact that neurological conditions for cognitive performance naturally vary between 
individuals as a consequence of genetic factors, education and other types of environmental 
exposures through the life span, also means that there could be differences on group levels 
between different birth cohorts. Typical advantages of belonging to a later birth cohort 
include higher education, a more favourable socio-economic situation, and better nutrition 
over the life span, all of which contribute to improve cognitive performance. One 
manifestation of this is the “Flynn effect”, meaning that persons at a certain age today 
typically have a higher intelligence than people of the same age had in the past [51]. The birth 
cohort effect constitutes one of the complications when ageing effects on cognition are 
determined by comparing the cognitive performance of persons of different ages. It is easy to 
forget that in a cross-sectional designs we are at the same time comparing groups of people 
who were born and who grew up under different social and material conditions.  
3.2.3 What is the Isolated Effect of Ageing on Cognition?  
The dramatic differences between estimations that consider, or do not consider, birth cohort 
effects are illustrated in figures 4 and 5, from Schaie (2005) [52]. The first figure gives the 
impression of a radical decrease in cognitive performance for four out of six different 
cognitive dimensions with increasing age. But when the estimation is based on intra-
individual changes, performance does not change noticeable with age until after 60 years for 
any of the dimensions (Fig 5) [52].  
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Fig 4. Estimated association between age and cognitive performance for six cognitive 
dimensions based on cross-sectional data. (From Schaie, 2005 [52]) 
 
 
Fig 5. Estimated association between age and cognitive performance for six cognitive 
dimensions based on intra-individual changes with age. (From Schaie, 2005 [52]) 
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To complicate things further, birth cohort effects have not only been demonstrated on levels 
of performance at different ages, but also on cognitive trajectories over age[53]. In other 
words, even if a certain birth cohort is followed longitudinally, the resulting trajectory of 
cognitive performance over age may differ compared to a cohort that was born earlier or 
later, and then followed and measured over the same age span. Such a birth cohort effect on 
cognitive trajectories is illustrated in Figure 6 for a younger and older cohort, but with 
overlapping age periods, from a study by Finkel et al[53]. Cognitive performance during the 
overlapping periods was always higher for the younger cohort, consistent with the Flynn 
effect (see above) [51]. But by only considering the younger cohort (the dashed curves), 
cognition appears stable or to slightly deteriorate with age, also during age spans when the 
older birth cohort increased in cognitive performance, creating a more curvilinear relationship 
(the solid line). The only exception for this difference in slopes was for processing speed, the 
only dimension where ageing seems to have a similar effect on the trajectories across these 
two birth cohorts.  
 
Fig 6. Illustration of birth cohort effects on trajectories of cognitive performance over age for 
two birth cohorts. From Finkel et al, 2007 [53]. 
A third source of contamination with age, even in longitudinal studies, is the effect of 
terminal decline. This concept implies that at a very late stage of life all functions in the body 
typically decline. If terminal decline will also affect cognitive performance, this effect will 
then be contaminated with the affect of age per se. If so, to what extent is the trajectory slope 
seen in old age, even in longitudinal studies, a reflection of terminal decline in the cognitive 
domain? Terminal decline effects in cognition do indeed seem to exist, and has been shown 
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to start at least three years before death[54]. According to one study this decrease in cognitive 
performance begins on average 7.7 years before death[55], and one study identified at 
terminal decline onset specifically for processing speed almost 15 years prior to death in 
dementia-free persons[56]. Others have shown that it is important to consider early and 
subclinical dementia, a common condition for old persons, when estimating terminal decline 
effects on cognition, and the effect of terminal decline is indeed smaller when persons with 
this condition are excluded[57]. An alternative study design to separate these effects from the 
effects of ageing itself is therefor to calculate age from death, rather than using the common 
measure of chronological age from birth. With such an approach it should be possible to 
adjust the cognitive trajectories in old age for the influence of terminal decline, that is not part 
of ageing per se, and in addition adjust for the previously discussed birth cohort effects, to 
better isolate the real effects of ageing on cognition.  
While the scientific community of ageing research has clearly moved away from a purely 
cross-sectional approach to estimate ageing effects on cognition, it is till rare to find studies 
that also consider the fact that progressively more study participants are affected by terminal 
decline with increasing age, irrespectively of when they were born. I found no study that tried 
to map cognitive trajectories with increasing age that simultaneously adjusted for birth cohort 
effects, terminal decline effects, and effects of clinical and pre-clinical dementia. We saw 
previously that the effect of adjusting for birth cohort effects dramatically changed the 
relation between age and cognition up to at least 60 years. Additional research is needed to 
describe what happens to these trajectories after the age of 60 when adjustment for terminal 
decline and subclinical dementia are also added to the models. 
Related to the unorthodox approach of calculating age from death, rather than from birth, is 
the recent distinction between chronological and biological age. In line with the above, two 
persons at a certain chronological age may show very different levels of functioning in terms 
of ageing. In common language, a person may “seem much younger (or older) than he or she 
is”, possibly due to differences in genetic factors that influence methylation rates and due to 
life-style differences that influence the rate of biological ageing. According to advocates of 
this distinction, biological age may be a more adequate description of a person’s real age, 
than what can be inferred from the year the same person was born. 
3.2.4 Conclusions 
In summary, there are many different theories of ageing and none of them enjoys unanimous 
support from the scientific community. The effect of ageing on cognition could therefore be a 
function of anything from a pre-programmed down-regulation of energy expenditure and/or 
brain plasticity with an evolutionary origin to an accumulation of unfortunate events in 
combination with less efficient repair mechanisms that causes deterioration of all body 
systems in old age, including the brain, and/or in systems that are vital to the brain. In order 
to measure ageing effects on cognition, it is important to separate ageing effects from the 
effects of other parameters that are associated with ageing, but is not ageing, such as 
differences between birth cohorts, effects of age-related diseases, and terminal decline. When 
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efforts have been made to control for any of these factors, the effect of ageing on cognition 
has been considerably reduced, and sometimes practically vanished. To evaluate the 
hypothesis that ageing in itself has an effect on cognition, also after control of age-related 
factors that is not ageing per se, the progressively larger variation in cognitive performance in 
older cohorts has to be accounted for, including the fact that some very old persons have a 
relatively preserved cognitive ability. One of the greatest challenges in estimating ageing 
effects on cognition is to control for under-lying neuropathological conditions that even its 
carrier may be unaware of. These conditions will be discussed in the next chapter. 
 
3.3 COGNITIVE HEALTH IN OLDER AGE 
The fact that we live longer naturally will have consequences for the prevalence of the most 
age-dependent diseases. For many of these diseases, like cancer and cardio-vascular diseases, 
we have witnessed impressive advances in medical technology and treatment that have made 
it possible to control these diseases, and, especially in the case of cancer, even cure many of 
them. For others, like Alzheimer’s disease and several other dementias, no treatment has still 
been discovered to prevent, cure or efficiently halt their progression once a person has been 
afflicted[58]. As a consequence, with a growing proportion of old persons, especially the 
prevalence of dementia diseases has increased dramatically and continues to do so. Today 
around 50 million persons in the world are estimated to suffer from a dementia disease, with 
Alzheimer’s disease as the most common type. By 2050 this number is projected to have 
surpassed 130 million, with dramatic consequences for the many afflicted individuals and 
their families, but also for societies in terms of drastically increasing care needs and 
costs[58]. While this increase in prevalence is driven by the fact that more and more people 
reach a higher age, there is however no indication that incidence, i.e. the risk for a certain 
individual at a certain age to have dementia, is increasing. On the contrary, some new 
evidence suggests that dementia incidence for different age cohorts of old people may 
actually be decreasing, at least in some parts of the world[58-60]. Although encouraging, this 
possible trend is however not even close to make up for the increased prevalence of dementia 
driven by the growing number of persons who live longer than before as increasing age is the 
primary driving force for dementia; for each five years after 70, the proportion of persons 
with dementia approximately doubles [61](Figure 7). The fact that age is so strongly 
associated with dementia incidence does however not mean that dementia is a feature of 
natural ageing, just as other age-related diseases like cancer or type 2 diabetes are not. Instead 
they are diseases that people in older age are more likely to get.  
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Fig 7. Increase of dementia prevalence with age in three different populations at different 
time points, with stratification for gender. (From Wu et al, 2015 [61]) 
 
3.3.1 Dementia  
Dementia is an umbrella term for several neuropathological conditions with the common 
denominator of significantly impairing cognitive function. Depending on the type of 
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neuropathology, the types of cognitive domains mostly affected vary, as do the course of 
progression for each type of dementia. Without going into the details of different dementias 
and their different neurological consequences, the most common form of dementia, 
Alzheimer’s disease (AD), usually affects memory functions initially, while frontotemporal 
dementia (FTD) usually has its early main effect on executive functions and regulation of 
emotions. Vascular dementia (VAD) is usually associated with more heterogenous symptoms 
that can vary due to the location and severity of the brain lesion. This exemplifies the 
differences in brain structures that are typically affected in the early stages of each of these 
common forms of dementias; typically the hippocampus area in AD, with consequences for 
working memory, the frontal regions in FTD with consequences for behaviour regulation, and 
failures of the vascular system to support various brain areas in VAD, with the consequence 
of affecting various brain structures with insufficient supply of oxygen and nourishment. But 
even more common than to have a single, specific type of dementia, is the case of mixed 
dementia. AD is the most common dementia disease and the most common scenario is to 
have AD mixed with some other dementia, often VAD especially among older persons [62] 
[63]. As AD is the most common type of dementia, either alone or in mixed dementia, and as 
two of the works in this dissertation has AD as a specific outcome, I will now give more 
specific attention to this particular type of dementia. 
3.3.2 Alzheimer’s Disease (AD) 
The first record of AD was made by the German physician Alois Alzheimer in 1906 and the 
disease was then named after him. His patient, Auguste Deter, was diagnosed with this 
condition at only 51 years of age and died six years later. Through brain autopsy, Alzheimer 
and two Italian colleagues identified two types of abnormalities in her brain, amyloid plaques 
and neurofibrillary tangles (NFT), features that still today are used to describe the core 
characteristics of Alzheimer’s disease. Today, an important distinction is usually made 
between the familial and late-onset types of AD. The rare familial type, with a prevalence of 
only around 1-2%, is a type of early-onset AD, often afflicting a person already between 40 
and 50 years of age, or even earlier. As the inheritance is autosomal dominant, children to a 
parent with this mutation will have a 50% chance of inheriting the allele, that can either be a 
mutation in the amyloid precursor protein (APP), presenilin-1 (PS1), or presenilin-2 (PS2) 
genes. As far as is known, a person with the mutation will inevitably also get the disease if 
the person lives long enough. Besides the differences in terms of the genetic determination 
and the typical age of onset (averagely around 40 instead of around 75), the familial form of 
AD resembles late-onset sporadic AD in many ways. Some persons may also get the familial 
type of AD later in life, when they are over 65, which should make it virtually impossible to 
distinguish them from sporadic cases as the phenotypes are largely overlapping in older age 
[64]. As AD is very rare before 60 or even 65, with a prevalence of around only 35 persons 
per 100 000 in the age range 45-65 years [65], some researchers have suggested to simply use 
an age cut-off to distinguish the two types, usually at 65 or 60 years of age, and to use the 
terminology early versus late onset AD, without reference to the distinction in heritability. 
One argument that the two types of AD represent a continuum of the same disease is, besides 
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similarities in phenotypes [64], that the prevalence of AD in different populations is typically 
doubled for every progressive five-year age cohort already from 35 years of age [65], i.e. not 
only from 60 or 65 as is typically reported for dementia prevalence (e.g. see Fig 7). Some 
have also argued that the distinction between heritable and sporadic Alzheimer’s disease is 
not valid, but that heritability is rather representing a continuum so that Alzheimer’s disease 
at younger age to a larger extent is genetically determined and in later age relatively more by 
non-genetic factors. It is beyond this thesis to evaluate these claims, but it is important to note 
that most research on animal models with the aim of developing drugs against the common 
late-onset AD seem to be based on the assumption that familial AD is basically the same 
disease as late onset AD; the common method in this type of research is to study 
pharmaceutical effects on animals with genetic mutations of the same kind as found in 
familial AD. Evidence against such an assumption is that although the two phenotypes are 
similar they are not identical. Symptoms differ in some respects (e.g. in terms of motor 
functions), and biologically, familial AD is typically associated with higher amyloid burden 
and a more aggressive progression of the disease [64]. The difficulty in identifying genes of 
relevance for late-onset AD, except for the relatively modest impact of the ApoE4 allele (in 
comparison to an APP, PS-1 or PS-2 mutation) could also indicate a difference in disease 
mechanisms. Another indication in the same direction may be that drugs that have 
successfully relieved animals from their amyloid burdens, have not yet relieved humans with 
the common sporadic type of AD from their symptoms – or been able to halt the progression 
of the disease in them[58]. 
3.3.3 The role of ApoE4 in AD 
Apolipoprotein E (ApoE) is a lipoprotein that can be produced in the liver and in astrocytes 
and has several biological roles, including cholesterol transport to the liver and, in the 
nervous system, also transport of fatty acids and phospholipids. It is coded by the same gene 
on chromosome 19, and exists in three isoforms called ApoE epsilon 2, 3 and 4. When the 
alleles combine it can thus theoretically result in six different combinations. The prevalence 
of the three isoforms vary somewhat across populations, but ApoE3 is the most common with 
a global prevalence of 78.3% and the prevalence of the rare ApoE2 isoform 6.4%[1], and in 
some populations completely absent[66]. The third isoform, ApoE4, is associated with a 
higher risk of Alzheimer’s disease and also elevated risk of cardiovascular disease and a 
poorer prognosis after traumatic brain injury [67]. There is also evidence for ApoE4/4 
implying a higher risk of Alzheimer’s disease than the more common ApoE3/4 combination 
[66]. Conversely, ApoE2/3 implies a decreased risk of AD. As mentioned, the prevalence of 
the three isoforms varies somewhat across populations, and this is especially true for ApoE4 
[68]. In the Nordic countries the prevalence of ApoE4 is typically around 25-30% [68], while 
the prevalence in the Caucasian population at large has been estimated to around 15% [69]. 
One meta-analysis estimated the average odds ratio for Alzheimer’s disease to 2.7 (CI 2.2. – 
3.2) for ApoE3/4 carriers versus non ApoE4 carriers (ApoE3/3 carriers) in the Caucasian 
population[69]. This means that many persons without this allele also get the disease. Several 
studies suggest that even if ApoE4 may be a risk factor in itself, the risk magnifies when 
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ApoE4 is combined with non-genetic risk factors such as physical inactivity, alcohol and 
smoking [70], living alone[71], and feelings of hopelessness[72]. The mechanisms behind the 
risk increase for Alzheimer’s disease as a function of ApoE4 status is unknown, but several 
studies have reported that ApoE4 is also associated with AD biomarkers such as a higher 
amyloid burden and neurofibrillary tangles[66]. The possibility of an indirect link is indicated 
by the fact that ApoE4 is also associated with other risk factors for dementia such as 
depression [73] and cardiovascular disease [74]. While ApoE4 probably does not affect 
cognitive performance negatively in younger age, it has been reported to alter brain function 
in other ways, e.g. increased coactivation of brain areas in the default mode network (DMN), 
as measured through fMRI[67]. 
3.3.4 The amyloid β cascade hypothesis in AD 
The probably most influential hypothesis concerning the biological mechanisms behind AD 
is the amyloid β cascade hypothesis, initially suggested by John Hardy and Gerald Higgins in 
a Science article in 1992 [75]. The core of this hypothesis is that accumulation of the amyloid 
β protein, leading to amyloid plaques in the brain, is the cause of Alzheimer’s disease, and 
that other biological events associated with Alzheimer’s disease that follow are a direct result 
of this amyloid accumulation. The theory has since been criticised and modified, also by John 
Hardy himself [76] [77], but is still the cornerstone in most biologically oriented research on 
AD. Fig 8 represents a common present view on the sequence of events in AD, following the 
proposed initial accumulation of amyloid β.[78]. 
 
Fig 8. Sequence of events with measurable biomarkers in the development of AD. 
MCI stands for Mild Cognitive Impairment. From Jack et, 2010 [78] 
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This proposed sequence of events is characterized by hyperphosphorylation in the tau protein 
in the second phase. This protein has a central role in microtubuli for intracellular transport 
and for the architectural integrity of the neuron. As the disease develops, progressively larger 
areas of the brain are affected through both synaptic loss and cell death, leading to 
measurable atrophy in the brain, resulting in enlarged ventricles that can typically be 
observed in brain images also in relatively early stages of AD development. As these changes 
develop, they will eventually lead to impaired memory and deterioration of other cognitive 
functions, and eventually clinical symptoms to enable diagnosis [78]. AD is a progressive and 
lethal disease with an average survival time after diagnosis of 3-4 years [79].  
The emphasis on amyloid β as the primary causal agent in AD has been questioned, as some 
observations seem at least party inconsistent with such a role. For example, there is no 
association between amyloid burden and cognitive decline in AD [80], amyloid plaques are a 
universal phenomenon in persons with AD, but is also common in old persons without any 
symptoms of AD or other cognitive decline[81], amyloid β  has recently been reported to 
have antimicrobial properties and be part of the innate immune system [82], and, as 
mentioned previously, pharmaceutical interventions targeting amyloid β, while relatively 
successful in mouse models, have failed to improve symptoms in humans and in some trials 
even worsened the symptoms [83] [81] [84]. One possibility for the pervasiveness of the 
amyloid cascade hypothesis is that amyloid β accumulation seems to be a universal 
phenomenon in persons who will develop AD. But, to apply simple logics, an association 
between these two events is no proof that there is also causation involved, and even if it is, 
that it has to be in the assumed direction. If the association indeed reflects causation, could it 
be possible that the direction of causality is opposite to that proposed by the amyloid β 
cascade hypothesis? Some critics of the amyloid β cascade hypothesis have suggested 
precisely this alternative possibility[85], and even John Hardy, the originator of the amyloid β 
cascade hypothesis[75], has mentioned this as “a worrying possibility”[76].  
3.3.5 Strategies to discover new mechanisms  
Alzheimer’s disease, like any other disease, can be described and explained at different 
levels, and the previous discussion about the role of amyloid β should illustrate this important 
difference between description and explanation. It seems unclear whether amyloid β 
accumulation causes the disease, is a characteristic of the disease, or perhaps even a 
protective reaction to the disease. In contrast, tau phosphorylation and the related formation 
of neurofibrillary tangles (NFT), and loss of synapses are most certainly integral 
characteristics of the disease itself, directly related to its consequences for cognition, 
behaviour and the clinical picture[78]. In the case of amyloid β, growing doubts concerning 
its role, while recognizing the fact that amyloid β accumulation is always found in early 
stages of AD, has instigated proposals to look at the wider, but still largely unknown, role of 
this peptide in biological systems in order to find new mechanistic clues[76]. After all, there 
is no reason to believe that evolution equipped us with this peptide in order to cause 
Alzheimer’s disease.  
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To go from characteristic to explanation, i.e. to look “upstream” from any significant 
characteristic of the disease, is to look for precursors, for what may be behind these 
characteristics of the disease. Synaptic loss has been proposed by some as the most 
characteristic and universal feature of AD[86], and possibly also of other dementias[87]. An 
“upstream strategy” in the search for causal mechanisms based on this characteristic, could 
then be to look at neurotrophic factors, including brain-derived neurotrophic factor (BDNF), 
as they are of critical importance for neurogenesis, synaptogenesis and neuroplasticity[88,89] 
[90] [91-94]. In other words, if Alzheimer’s disease is caused by dysfunction related to nerve 
growth, synaptogenesis and neurogenesis, will we find new clues to understand and cure 
Alzheimer’s disease if we look for factors that regulate BDNF functionality? That 
neurotrophic factors are hampered in AD is not only indirectly indicated by synaptic loss in 
AD, but also by an inverse association between BDNF levels and severity of neuropathology 
[95].  
The strategy to look for “what is behind” biological phenomena can easily be criticised for 
being reductionist; there is always something behind everything – and the search never ends. 
Instead of arriving at an explanation, the risk is that we find yet another level of descriptive 
characteristics. A complementary strategy to understand the mechanisms of Alzheimer’s 
disease and other dementias is to look for associations at a very different level, at the level of 
behaviours, life styles and psychosocial factors. One of the main points of this thesis is that 
understanding of Alzheimer’s disease and other dementias cannot come only from 
descriptions of biological events at an atomistic level. On the other hand, an association 
between a certain behaviour or emotional condition during the life course, and incidence of 
dementia decades later, does not add much to the understanding if we cannot even imagine a 
link between such an association and the biological events that lead to the disease. They 
should all be regarded as pieces of the same puzzle. 
3.3.6 Life-course Exposures and the Brain Reserve Hypothesis 
Classical experiments by Mark Rosenzweig, Marian Diamond and colleagues have 
demonstrated that an enriched environment can increase cortical thickness and total brain 
weight in rodents[96]. Enriched animals also showed a richer neuronal dendritic network and 
improved learning abilities compared to less stimulated individuals[97]. More recently it has 
also been shown that an enriched environment can increase brain levels of neurotrophins such 
as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) [98]. Some 
experimental studies also suggest that social stimulation may have similar effects as enriched 
environments and physical exercise[99,100]. 
A large number of epidemiological studies on humans have shown that especially 
education[101] [102], but probably also other forms of intellectual stimulation, is associated 
with lower dementia risk[103]. A common explanation for this effect is the brain reserve 
hypothesis[104]. The core of the brain reserve hypothesis is that a brain with rich neural 
networks, at least partly as a result of prior stimulation, has better ability to resist and 
compensate against an underlying neurodegenerative disease process[105]. Empirical data 
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support a number of factors that seem to help building such a brain reserve, including support 
for education, a range of other intellectual activities, physical exercise - and social 
factors[106]. Related to the brain reserve hypothesis is also the finding of a probable link 
between a higher cognitive capacity / intelligence early in life and a lower risk of dementia in 
old age[107].  
The brain reserve hypothesis may not seem very original in the sense that it adds little to, and 
builds closely on, previously well-established characteristics of the nervous system, such as 
its plasticity; it has long been known that the brain is capable of repairing itself and of 
reallocating neural processes after injury to regions adjacent to the injured one and that this 
ability is more pronounced in younger individuals. As mentioned above, the effects of 
enriched environments on neural networks, dendritic spines and synapses, which are all 
related to the brains capacity to be modified by experience, are also well known.  
Another weakness of this hypothesis is that it seems mainly relevant for explaining individual 
differences in the latency between the point of disease initiation and diagnosis. There is no 
evidence that this hypothesis has anything to say about factors that may prevent the disease 
process from being initiated in the first place. This point is illustrated by recent findings that 
higher education is often associated with higher cognitive performance, but not with less 
cognitive decline in later life[108,109]. This should mean that persons with high education 
typically have a longer period of cognitive decline before their cognition has dropped to a 
level where criteria are met for a dementia diagnosis and when it does, that the disease at the 
neuropathological level has reached a more advanced stage[110]. This may also be the reason 
why a highly educated person typically has a faster progression of the disease after the time 
of an AD diagnosis[108]. In other words, education does not protect against dementia, but it 
typically delays its diagnosis.  
On the other hand, any knowledge that is relevant for postponing cognitive decline to a 
debilitating level are welcome, both in terms of adding more years with a higher quality of 
life for the affected individual and in terms of attenuating rampant societal costs for dementia 
care in advanced stages of the disease. In addition to this, there is epidemiological evidence 
that the same type of activities that may build brain reserve capacity in a life-span 
perspective, possibly can have such an influence also in later life[111], perhaps even if 
exercised during early stages of cognitive impairment. Several clinical trials are on-going to 
test this hypothesis in elderly people, some of them in early stages of cognitive impairment 
and the results are so far promising[112].  
As dementia is a progressive disease with a confirmed preclinical phase of up to twelve 
years[113], this means that a decline in cognitive ability may have lasted varying lengths of 
time for a certain individual at the time of diagnosis, depending on at least three factors: a / 
baseline level of cognitive functioning at the point when the subclinical disease process 
started, b / the rate of cognitive decline from this point and onwards and c / neuronal and 
other resources available to the individual in order to compensate for the progressive 
degenerative process. All of these factors should be related to the amount of brain reserve the 
  31 
individual had accumulated at the time when the neurodegenerative process started - and 
possibly also on brain reserve-relevant activities after that point. 
3.3.7 A Multitude of Life-style Associations not unique for Dementia: What 
does it mean?  
It is common in medical research to look for causes and mechanisms that are specific for 
different diseases. In research on Alzheimer’s disease the focus on the role of beta-amyloids 
and tau phosphorylation exemplify such an approach. Although it seems obvious that specific 
mechanisms such as these, unique for any disease, need to operate on a micro level for a 
specific disease to develop, some argue that non-specific disease mechanisms, as well as 
protective mechanisms against the same diseases, may be important to recognize. What is 
meant by a “non-specific disease mechanism”? It is related to a factor that increases the risk 
of disease in a general way, and that is not specifically tied to any specific disease. Ageing 
itself could in this perspective be considered as a factor that increases the risk for disease in a 
non-specific way; with increasing age the biological system gets more fragile and will 
become less able to withstand health threats of many kinds, from a virus infection to cancer. 
Sleep is intimately related to immune function, and poor sleep during an extended period can 
also be considered as a non-specific health threat, possibly due to its impact on 
immunological efficiency, with many possible specific disease outcomes as possible [114].  
A related assumption is that psychological and biological phenomena are closely linked and 
that their interrelatedness is a key to understand mechanisms behind health and disease. This 
idea can be exemplified by the biological consequences of mental states, such as stress, grief 
or depression, which are reflected in bodily processes that could have health consequences, 
rather than being isolated from these processes.  
These two ideas of a general, or non-specific, health mechanism and the interrelatedness of 
psychological and biological phenomena are corner stones in the psychoneuroimmunological 
approach [115]. It also rests on the assumption that efficient communicative pathways exist 
between the immune system, the nervous system and the endocrine system, an assumption 
that seems empirically supported [116]. The generality of this approach, relates to the 
protective role of a well-functioning immune system against practically any kind of heath 
threat, and conversely that immunological dysfunction may have a wide range of disease 
consequences.  
Although the term was coined as late as 1983, the basic assumptions behind 
psychoneuroimmunology are not new; to “rest and recover” is probably still a very common 
medical advice when a person feels sick, with or without other medical interventions. The 
notion that immune-disruptive exposure to e.g. stress, bad sleep or negative emotions 
constitute a general health risk is both part of ancient and common wisdom.  More recently, 
empirical studies have confirmed that one and the same psychological stressor, with a high 
likelihood of immunological relevance, can indeed lead to a range of different diseases [117]. 
But can it also lead to Alzheimer’s disease and other dementias?  
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Before addressing this question directly, we will consider the diversity of factors that have 
been suggested as protective against cognitive impairment. Among these are physical 
exercise [118], a generally active life style [119], social interactions [120], and a 
“Mediterranean” diet (a large proportion of vegetables, fish and fruit) [119]. Among 
suggested risk factors we find loneliness [121,122], depression [123], hopelessness [72,124], 
stress [125,126], obesity [127,128], midlife hypertension [129], and frailty [130]. It should 
be evident that few, if any, of these factors have a specific relevance to explain cognitive 
impairment, but equally well apply to many other health conditions. Is this an indication that 
they operate through a common factor? If so, is the immune system a possible candidate?  
Before addressing this question, it should be noted that the hypothesis of a non-specific health 
mechanism does not preclude the possibility that a factor could work through such a 
mechanism, thereby contributing to disease proneness in a general way, but in addition have a 
more specific risk impact. To exemplify, smoking undoubtedly has a specific link to impaired 
lung function and increased risk of lung cancer. But smoking may in addition present a 
burden on the immune system, thereby resulting in elevated risk for a range of other diseases. 
According to some studies, dementia is one of them[131]. Having a chronic disease may in a 
similar way present an added burden on the immune system, and thereby in a non-specific 
manner also increase the risk of other diseases to develop. To exemplify, multimorbidity is 
more common in persons with diabetes, and while some of the links between diabetes and 
other diseases may be more direct, leading to different pattern of comorbidity compared to 
comorbidity in persons with other chronic diseases [132], persons with a chronic disease like 
diabetes have been found more vulnerable to develop multimorbidity when they are also 
exposed to other risk factors [133]. From a psychoneuroimmunological perspective, this may 
be due to the pre-existing immunological burden from the original chronic disease.  
On logical grounds it could be argued that whatever specific events that at a micro level 
constitute a certain disease, there has to be a chain of events leading from a risk-related factor 
and, at the end of the line, the specific events and processes that constitute and characterize 
the disease, events that in the case of Alzheimer’s disease are exemplified by tau 
phosphorylation and synaptic loss. If we move upstream from tau phosphorylation, beta-
amyloids seem to have an important role, although not yet fully understood[134]. Which are 
the chances that immunological mechanisms reach into these processes and affect their 
initiation and outcome? Without a credible bridge from behaviour and emotions to 
immunological consequences, and then to immunology-related consequences of relevance for 
disease-specific events and processes, the psychoneuroimmunological theoretical framework 
may not appear as a convincing one.  
For at least some of the suspected emotional risk factors for Alzheimer’s disease and 
dementia, such evidence now seems to exist; in the case of depression, it is known to increase 
pro-inflammatory reactions in the brain, including increased levels of cytokines[135]. These 
reactions in turn have been proposed as implicated in the development of Alzheimer’s 
disease[136,137]. One experimental study showed that increased levels of glucocorticoids, 
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which in humans are related to depressive feelings, anxiety and stress, led to increased beta-
amyloid and tau pathology, with increasing APP levels and beta-APP cleaving enzyme, in an 
animal AD model[138]. This should mean that also Alzheimer’s disease could be one of 
many possible disease outcomes from a psychoneuroimmunological perspective. A schematic 
summary of this link between depression, immunology and AD is found in figure 9, adapted 
from Irwin et al, 2007[139] 
 
Fig 9. A schematic illustration of brain-immune interactions in depression and how it relates 
to dementia. 
Adapted from Irwin, 2007[139] 
 
3.4 THEORETICAL AND METHODOLOGICAL CONSIDERATIONS  
The long pre-clinical period during which symptoms develop gradually and subtly, presents a 
major methodological challenge to identify life style and environmental factors that can 
increase the risk of the disease. The imprecise nature of the pre-clinical period can also lead 
to dramatic over estimation of its length without a proper distinction between 
antecedents/predictors of the disease – and the disease itself.  
3.4.1 The Difference between AD Diagnosis and AD Neuropathology 
An important distinction in this regard is between carrying the disease (at the 
neuropathological level) and being clinically diagnosed with the same disease, a distinction 
we previously discussed in relation to the question of high education being protective against 
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dementia or not (see section 3.3.5). Measurable cognitive decline has been demonstrated to 
start up to twelve years before clinical diagnostic criteria are fulfilled[113], which means that 
any longitudinal study with a follow-up time from baseline of less than twelve years runs the 
risk that any association between a factor at baseline and the subsequent diagnosis of a 
disease can reflect influences of subclinical phases of the same disease already at baseline, 
i.e. reflect reverse causation. To exemplify, if social interactions at baseline is found to 
predict dementia a few years later, this association could mean that that an underlying disease 
had already started to affect the person’s social behaviour at the start of the study. To avoid 
the risk of reverse causation in dementia research, long follow-up times are needed and 
preferably also baseline measurements when the participants are relatively young. It is 
uncommon that both these methodological requirements are fulfilled, and the CAIDE Study, 
on which three of the studies in this thesis are based, is one of very few examples. 
3.4.2 The difference between Precedents and Characteristics 
Another important distinction in understanding Alzheimer’s disease is that between 
precedents and characteristics of the disease. To exemplify, if accelerated cognitive decline 
can be demonstrated ten years before diagnosis, compared to persons of the same age who 
will not become diagnosed, it should mean that the observed cognitive decline that preceded 
the diagnosis is not only a precedent, but in addition an early manifestation of the disease at 
the neuropathological level. But if persons with a lower IQ already before 20 years of age are 
more likely to become diagnosed with AD when they get old, as has been found in the 
famous Nun studies by Snowdon et al.[107], that does not mean that their AD started already 
in childhood. First of all, AD is a progressive and lethal disease, meaning that lower 
intelligence in itself cannot be a manifestation of the disease, unless a progressive decline in 
intelligence and/or cognitive ability can be demonstrated. A more likely explanation is that 
people with lower IQ can be diagnosed earlier, which, as in the case with low education/a 
lower brain reserve, easily can be confused with a higher risk of actually getting the disease. 
Another possibility is that people with lower IQ are more vulnerable to develop AD. In 
neither of these cases does it mean that this exemplified antecedent is a symptom of the 
disease itself. Difficulties in understanding this distinction may lead to exaggerated and 
unwarranted claims concerning the typical age when AD starts to develop on the 
neuropathological level.  
3.4.3 Main Methodological Approaches in Dementia Research: Pros and 
Cons 
Main methodological approaches in dementia research include experiments on AD animal 
models, intervention studies on humans and epidemiological association studies on humans. 
Unfortunately none of these approaches alone offers a royal road for dementia research, as we 
shall see.  
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3.4.3.1 Animal Studies: Pros and Cons  
The main advantage with animal studies, although some would strongly disagree, is that 
ethical limitations are less of a problem. Animals can be genetically modified, exposed to 
high levels of different exposures in a systematic and controlled fashion and they can be 
killed (“sacrificed”) at a time when it is most convenient for immediate identification of 
structural and biochemical effects. In the case of drug trials, this means that at the time when 
the drugs are tried in humans, successful outcomes in preceding phases on animals, reduces 
the risk of casualties, suffering and other adverse effects when the same drug is tried in 
humans. In the case of non-drug animal experiments, the effects of various environmental 
exposures can be invaluable to discover important brain mechanisms or establish health 
effects from a specific exposure. One example of the first is the research that dramatically 
illustrated the effect of environmental stimulation on neuronal density and cortical 
thickness[96]. Animal experiments confirmed smoking as causative for lung cancer, a 
demonstration with enormous impact on public health. 
The main problem with animal studies is that animals are animals – not humans. If we are 
interested to see if depressive feelings, cultural activities, singing in a choir or mindfulness 
meditation are beneficial for cognitive health, animal studies have little to contribute. For 
other factors, like physical exercise or intellectual stimulation, animal experimentation may 
however seem a less remote possibility. In the case of AD research, mice do not naturally get 
a disease that resembles AD, and, as mentioned above, genetically manipulated mouse 
models can yet only be made to carry some biological characteristic of the disease, like 
heavily elevated levels of amyloids, but in other respects share little resemblance with the full 
phenotype of human AD. In spite of huge advantages in terms of experimental control and 
the kinds of analyses that can be made, animal experimentation, especially on mice, should be 
either non-feasible or have little generalizability to directly test hypotheses on either causal 
links to AD in humans, or cures against the disease. Development of new and more adequate 
AD mouse models could of course make such a conclusion less valid in the future than it 
probably is today.  
Even if there are doubts concerning the potential of animal experimentation to directly test 
hypotheses concerning causes and cures for AD in humans, for reasons mentioned, animal 
experiments can still be of value to test mechanisms that are related to AD in some way and 
to translate such findings into studies on humans. In other words, animal experiments can be 
valuable by generating mechanistic hypotheses of relevance that can then be tested on 
humans. Paper 4 in this dissertation is an example of such a translational approach. This 
paper builds on the hypothesis that neurotrophic factor dysfunction could be relevant for AD. 
Animal experiments have not only shown that environmental enrichment can produce 
synaptogenesis and improved learning ability in mice, but also indicated that BDNF 
availability in the brain is a prerequisite for this to occur[140-142]. Intuitively, AD in humans 
appears to represent the antipode of increased inter-neural connectivity, synaptogenesis and 
neurogenesis, plastic processes where BDNF seems to play central role - in combination with 
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different types of beneficial environmental exposures. With this in mind, the idea with Study 
4 was to see how different types of activity could affect BDNF levels in humans. This 
example brings us to consider pros and cons of experimental/intervention studies in humans. 
3.4.3.2 Human Intervention Studies: Pros and cons 
The general advantage of an experiment is that participant can be randomly assigned to 
different conditions, thereby evading the main problem of epidemiological association 
studies; that of self-selected groups and confounding influences from variables that differ 
between the groups, in addition to the predictor variable of interest. A classical parallel 
groups design with random assignment of conditions dispenses with the need to adjust for 
potential confounders; in a well-performed experiment with parallel groups, only one factor 
differs between the groups, the factor of interest. If there is a difference in outcome, it can be 
safely attributed to the causal influence of this independent variable.  
Besides the parallel groups design, or between-groups design, many other experimental (and 
quasi-experimental) designs exist [143]. While it is beyond the scope of this thesis to discuss 
all of them, mention should be made of a second major experimental design that, when 
feasible, is superior to a parallel groups design. This is the within-subjects, or crossover, 
design. In this design the different conditions are not assigned to different groups, but each 
individual is exposed to each condition and intra-individual differences in effects between the 
different conditions are compared. The advantage of this design refers to the fact that 
although individuals in a parallel groups design are randomized to the different conditions, 
they are each different from each other in many ways, although these differences are not 
systematically distributed between groups. This creates variability in effects within each 
parallel group that easily can mask the systematic difference between groups that is 
attributable to the difference between conditions. When each individual is compared to 
him/herself across conditions, the inter-individual “noise” in a parallel groups design is 
eliminated and the true effect of the intervention, if there is one, can emerge as a stronger, and 
potentially detectable, signal. In statistical terms, fewer participants are needed to attain 
sufficient power, compared to a parallel groups design. The main threat in this design is from 
sequence effects, but this is easily dealt with by systematically varying the order of conditions 
between individuals to attain a fully balanced design. When feasible, which is not always the 
case, a within-subjects/cross-over design is therefore always preferable to a parallel groups 
design. Paper 4 illustrates the application of a within subjects/cross-over design in an 
intervention study on healthy elderly humans.  
If the problem with animal experiments is that animals are animals and not humans, in a way 
the problem with a human intervention study is that humans are – humans. Humans are social 
animals that are sensitive to even the subtlest signal of a desired performance from 
experimenters. The experimenter effect, i.e. the effect of expectations that are more or less 
subtly communicated, has proven powerful[144]. The social nature of humans can also make 
us wanting to live up to expectation of others and in addition wanting to present ourselves in 
a favourable way to others, called the social desirability effect [145]. In other words, an 
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elegant experimental design is no guarantee that the results are trustworthy if the experiment 
was not carried out in a proper way in other respects to circumvent these and other threats, 
especially when the participants were humans.  
At the end of the previous section, we discussed how paper 4, an intervention study on human 
subjects, was inspired by results from animal experiments. In the translation of this into an 
experiment on humans, several drawbacks, in relation to an animal experiment, should be 
obvious. For ethical reasons, we did not want to measure BDNF levels in the brains of our 
participants, not even in their cerebrospinal fluids, which, from a purely scientific point of 
view, would have been the most relevant. The compromise was to measure BDNF in 
peripheral blood serum. This compromise made the interpretation of the results a lot more 
complicated and speculative than they otherwise would have been. 
No intervention study on humans can directly test if a certain exposure of interest will 
increase the risk of Alzheimer’s disease. This would not have been a problem with mice, not 
even if we would find mice that can develop AD of the human type. Instead, and for ethical 
reasons, we focused in that study on finding positive brain health effects, or rather, probable 
correlates of such effects. Human intervention studies are in practice limited to studying 
factors that can prevent dementia, rather than identifying factors that could cause the disease. 
From a clinical perspective, this is not a problem of course, but for more basic research 
questions concerning possible triggering mechanisms behind Alzheimer’s disease, human 
intervention studies are out of question. This is in contrast to both animal studies, and as we 
shall see, epidemiological association studies.  
Another problem with intervention studies is that many of the most important factors that 
have emerged from epidemiological association studies are not possible to assign to different 
persons in an experimental setting. For example, traumatic experiences, stress, depressive 
feelings – or any feelings, positive or negative, for that matter, cannot be “assigned” to 
persons because they belong to a specific group in an experiment. The potentially “positive” 
factors we finally chose in Study 4 were mindfulness, which could be seen as the opposite of 
stress, physical exercise and cognitive training. These choices were guided by ethical 
considerations and evidence from both animal experiments and epidemiological association 
studies.  
This brings us to another ethical dilemma in intervention studies to prevent dementia: what 
do we do with the control group? A control group should be a group that is not subjected to 
the factor of interest, e.g. a combination of stimulating activities. But if the researchers fear 
that they thereby deprive the unfortunate individuals that ended up in the control group of 
something that could prevent or delay dementia, does that not indirectly mean that they 
contribute to dementia developing earlier in them? On the other hand, if the control group is 
active in a way that does not make them disadvantaged in relation to the group that received 
the intervention, we are deliberately ruining the chances of testing the hypothesis the study 
was designed for. The solution is often an active control group that participates in something 
of probable benefit, but hopefully with less benefit than the factor of interest. The FINGER 
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Study[146] exemplifies this dilemma by offering the control group regular health advice and 
monitoring their cardiovascular health. After two years of intervention, both groups had 
improved their cognitive performance, although the “real” intervention group even more so 
than the active control[112]. The question then arises: what was the real effect of the 
intervention? Was the improvement in the control group, in spite of getting two years older, a 
retest effect, which is the purpose of a control group to control for? Or was it related to the 
activities, including social interactions that the control group performed in parallel to the 
intervention in the other group? Or to life-style changes inspired by the health advice? To 
balance ethical and methodological considerations in designing what a control group should 
do in an intervention study, often carried out over several years, represents a delicate dilemma 
for the researchers. 
A final problem with intervention studies on human subjects in dementia research refers to 
the previously discussed time difference between the point of diagnosis and the point of 
disease initiation (see section 3.4.1). The golden grail for researchers on Alzheimer’s disease 
is to find the answer to the question “What causes Alzheimer’s disease?” But with a 
preclinical period of at least 10-15 years, and due to ethical limitations previously discussed, 
human intervention studies have to limit themselves to the more trivial question: “How can 
we delay the progression of an Alzheimer’s disease that has already started?” To perform a 
proper experiment to answer the “golden grail question”, we would have to expose persons, 
probably already in midlife, to something we think will prevent them from having 
Alzheimer’s disease when they get old – and then wait 20 years to find out if we were right. 
To do that, in the first place we would need a hypothesis that, on the basis of existing 
knowledge, seems to have a very high probability of being correct – and to have a lot of 
confidence in that hypothesis to motivate us to even think about such a venture. We would 
also need long term funding and a lot of patience. Another option is to rely on nature’s 
experiments and on choices that people have made by their own will. That option is to 
conduct an epidemiological association study.  
3.4.3.3 Epidemiological Association Studies: Pros and Cons 
An epidemiological study typically establishes associations between a behaviour or a 
condition, e.g., smoking or feeling depressed, at some point in life with a subsequent 
outcome, e.g. a dementia diagnosis, rate of cognitive decline or structural characteristics 
found through brain imaging. But an association in itself is not synonymous with causation, 
only a necessary requirement. Another requirement for an association to be causal is related 
to time; that the proposed causal factor existed before the outcome that it allegedly caused. 
Although these conditions may seem trivial, many epidemiological studies claim causality 
from associations without having fulfilled them. Referring to the above-mentioned “holy grail 
question” in dementia, epidemiological association studies with less than 15 years of follow-
up cannot possibly ascertain that observations at baseline are causally related to the initiation 
of an Alzheimer’s disease process if the subclinical progress can be assumed to be at least 
more than 15 years, which most estimation say it is [147]. In addition, the risk of reverse 
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causation is obvious (see chapter 1 and 3.4.1). In the ideal case, the time of baseline has to be 
at or before the time window when a factor potentially could have the effect to initiate the 
disease process. We also have to consider that, as far as known, AD is a progressive disease 
once it has been initiated. No known studies have reported evidence that the disease can be 
stopped at earlier phases of this process, although many hope that earlier detection could 
break the trend of all failed attempts we have witnessed so far. If the disease process is indeed 
irreversible once it has started, what is the point of relating a candidate risk factor in parallel 
to the disease, only a few years prior to the stage when the same disease can be diagnosed?  
On the other hand, if there is an association and in addition the time window requirement is 
met, the epidemiological association study have some unique advantages over animal studies 
and intervention studies, in spite of its relative logical weakness. First of all, the target 
outcome, e.g. AD, can actually be included as outcome without ethical problems, and events 
or behaviours that are impossible to use as independent variables in an intervention study can 
be related to as they with this study design are part of natural exposures or individual choices. 
In a time when the pendulum has swing so heavily in the direction of intervention studies, 
these advantages are important to keep in mind. 
In addition, it is often possible to circumvent the requirement of very long prospective 
designs if it is possible to reliably establish events and circumstances retrospectively. The 
problem with retrospective data is often that these measures are unreliable, e.g. when they are 
established through interviews, especially if the interviewed person is old with some degree 
of cognitive impairment. Even in perfectly healthy persons, memory research has 
demonstrated that memories are often false and constructed and/or modified unconsciously in 
retrospect [148]. A better possibility is probably to use archival data, or reliable registers. The 
mentioned studies by Snowdon[107], where letters written early in life were found and 
analysed according to their semantic complexity, is a well-known example of this strategy. 
The CAIDE Study, on which three of the scientific papers in this thesis is based (1-3), also 
represents a creative way to build on data that was originally collected for another 
purpose[149], and to relate the detailed information from those measurements to data from 
clinical re-examinations up to more than 30 years later.  
The major drawback with all epidemiological association studies is identical to the strongest 
feature in experimental designs: that categories of participants have placed themselves in 
those categories, rather than through a procedure of randomization by the researcher. To deal 
with potential confounding variables is therefore a major challenge in these types of studies. 
A common procedure to do that is to identify variables that were measured and that show an 
association to either or both the predictor and the outcome, with addition of variables selected 
on the basis of theoretical relevance, and then to statistically adjust for the influence from 
these variables in order to isolate the unique association with the factor of interest. It is 
difficult to avoid a certain degree of subjectivity in this process and the pressure to generate 
statistically significant and publishable results in the academic world does not help to make 
this procedure more objective and reliable. Another problem is the variables that were never 
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measured and that potentially could have altered the associations. One example of 
adjustments that are rare in dementia research is personality. At the same time it is likely that 
personality factors affect both the choices and the life styles people have and in addition may 
be associated with health. In the end, it is impossible to adjust for “everything”, both for 
statistical and practical reasons. The relative advantage of an experiment in this regard is that 
the randomization process ideally accomplishes just that. 
When a sample is invited to participate in a study of this kind, it is a universal feature that 
some invited persons do not accept the invitation or that they later drop out. If these persons 
were a random sample from the total sample, this would not present a problem, but they 
typically are not. To estimate the effect of participation bias it is common to describe the 
characteristics of this non-participant subsample with the true participants. The results from 
Paper 3 illustrates that this may be insufficient. In that study we did not only have baseline 
data from both participants and non-participants, but through linked registers we also knew 
what the outcome (dementia incidence) was in the group that did not participate in the follow-
up. When we compared incidences between participants and non-participants we found a 
dramatic difference, indicating that participation bias may be a much larger problem than 
commonly assumed, even when the participation rate is as high as in the CAIDE Study 
(around 75% during the re-examinations). 
3.4.3.4 Concluding remarks 
From the above it should be obvious that dementia research cannot rely solely on any of these 
approaches, but need to combine them. This has been a fruitful strategy in other cases where 
the outcome of interest was ethically impossible to include as outcome in an experiment on 
humans. Perhaps the most famous example is the case of smoking and lung cancer. The 
conclusion of a causal relationship was arrived at by combining findings from 
epidemiological studies that found a higher incidence among smokers than non-smokers with 
findings in animal experiments where animals were exposed to cigarette smoke with lung 
cancer as a frequent result. Public health recommendations have led to decreased smoking in 
many countries, and as a result the prevalence of lung cancer has gone down dramatically – 
besides resulting in other kind of health benefits[15].  
Intervention studies are often regarded as the golden standard in dementia research, but it 
seems that a comparative evaluation of pros and cons should justify an important role for 
high-quality epidemiological association studies also in the future. 
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4 AIMS 
4.1 GENERAL AIMS 
The general aim of this thesis was to investigate the long-term impact of social and emotional 
factors for cognitive health in later life. The purpose was to accomplish this by applying and 
combining both epidemiological and experimental methods, and by building on different 
types of data and methods of data analysis. A further aim was to investigate biological 
mechanisms of possible relevance for associations between life-style factors and brain health 
in old age.  
 
4.2 SPECIFIC AIMS OF THE DIFFERENT STUDIES 
The first paper aimed to investigate the association between cohabitant status in midlife and 
cognitive health in later life and how ApoE4 status modified the association with Alzheimer’s 
disease. 
The second paper aimed to evaluate one of the hypotheses emanating from the first study; 
whether the increased dementia risk detected especially for widowed could reflect that 
feelings of hopelessness is a risk factor for cognitive impairment in later life. 
The third paper, also building on the results from the first study, aimed to investigate the 
separate and combined effects of living and feeling alone in midlife on the estimated risk of a 
subsequent dementia diagnosis, and in addition to evaluate how non-participation bias 
influences the estimation of these effects.  
The fourth study aimed to investigate effects of different activities on levels of brain-derived 
neurotrophic factor (BDNF) in healthy elderly persons. 
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5 PARTICIPANTS AND METHODS  
5.1 STUDIES 1-3 
The first three studies were based on the Cardiovascular, Aging and Dementia (CAIDE) 
Study, carried out in Eastern Finland. CAIDE is a large, population-based study focusing on 
vascular, life-style and psychosocial risk factors for cognitive functioning and dementia in 
later life. With baseline examinations carried out already in midlife and a long follow-up 
period, these data offer a unique opportunity to study the relevance of these factors for 
cognitive health in a life-course perspective.  
The participants in the CAIDE Study were the survivors in 1997 of four independent 
populations samples, originally investigated between 1972 and 1987 in Eastern Finland as 
part of the North Karelia Project and the WHO MONICA project. The original purpose of 
these investigations was to investigate cardiovascular health and life style factors that could 
potentially explain an exceptionally high incidence of cardiovascular diseases and mortality 
in Finland, the highest in the world for young men at the time [149]. Participation rate was 
high, ranging from 83% to 93% [150]. The protocols for these baseline survey methods at 
baseline were standardized to comply with international recommendations and followed the 
WHO MONICA protocol, or were similar to these [151]. 
The Cardiovascular, Aging and Dementia (CAIDE) Study was later initiated to use data from 
these investigations in order to study longitudinal associations between health/life style 
factors in midlife and cognitive health in later life. Thus, in 1997 a random sample of 2000 
survivors between 64 and 79 years were invited for a first re-examination that took place 
during the following year, and then to a second re-examination that took place between 2005 
and 2008. In addition to the same measures that had been applied at baseline, when the 
participants were in their midlife years, the re-examinations included screening for cognitive 
impairment and careful clinical diagnosing for possible cases of mild cognitive impairment 
(MCI) or any specific type of dementia. (For further details on diagnostic procedures, see 
Paper 1.) 
Of the 2000 persons who were invited for the re-examinations in 1998 and 2005-2008, a total 
of 1551 persons accepted and fully participated in one or both of these re-examinations. In 
addition to re-examination data on these participants, we linked register data on dementia 
diagnoses and mortality from various register sources for all the 2000 persons who were 
initially selected to form the CAIDE Study population. Figure 10 schematically summarizes 
the design, including both re-examinations, and with cognitive health, MCI and dementia as 
outcomes. Table 1 is a summary of demographic data, stratified for re-examination 
participation and with outcomes (with or without a dementia diagnosis) and mortality as 
found through linked registers (from paper 3 in this thesis). Studies 1-3 are part of the CAIDE 
Study; The CAIDE Study was approved by the ethical committees at Kuopio University 
Hospital in Finland (D nr. 24/97 and 124/2004) and Karolinska Institutet (D nr. 04-103).  
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Fig 10. Flow chart of the CAIDE study covering the time period from 1972 until December 
2009. 
 
Table 1. Characteristics of the CAIDE population, with stratification by participation in re-
examinations. (From paper 3) 
For continuous variables, values are means (SD). P-values are from one-way ANOVA 
analysis for continuous variables and from χ2 analyses for categorical variables. 
Baseline	variables	(N	=	2000)	
Full	CAIDE	
sample	
(N	=	2000)	
Stratified	by	re-examination	
participation	
Participants		
(N	=	1511)	
Non-
participants	
(N	=	489)	
p-value	
Age	at	baseline			 50.6	(6.00)	 50.3	(6.00)	 51.5	(6.00)	 <0.0005	
Gender	(%	female)	 62.50%	 62.30%	 63.00%	 0.828	
Feeling	lonely	(N	=	2000)	 22.40%	 21.20%	 26.30%	 0.022	
Cohabitant	status	(%	Non-cohabitants)	 21.90%	 20.20%	 27.30%	 0.001	
Education	in	years		 8.31	(3.35)	 8.59	(3.40)	 7.43	(3.04)	 <0.0005	
Systolic	blood	pressure		 146	(20.6)	 144	(20.0)	 151	(21.4)	 <0.0005	
Diastolic	blood	pressure	 89.9	(11.1)	 89.3	(11.0)	 92.0	(11.2)	 <0.0005	
KTL	cholesterol		 6.80	(1.24)	 6.75	(1.22)	 6.96	(1.31)	 0.002	
BMI		 26.8	(3.96)	 26.6	(3.78)	 27.4	(4.44)	 <0.0005	
Persons	with	feelings	of	hopelessness	(%)	 46.2%	 42.7%	 57.7%	 <0.0005	
Variables	related	to	outcome	
Age	in	1998	(N	=	2000)	 71.6	(4.07)	 71.2	(3.97)	 72.8	(4.17)	 <0.0005	
Persons	with	a	hospital	dementia	
diagnosis	(N	=	327)	 16.40%	 14.20%	 23.30%	
<0.0005	
Age	at	time	of	diagnosis		 79.4	(5.39)	 80.5	(5.02)	 77.5	(5.57)	 <0.0005	
Died	before	end	of	study	(N	=	738)	 36.90%	 28.40%	 64.10%	 <0.0005	
Age	at	time	of	death		 79.6	(5.38)	 80.4	(5.46)	 78.5	(5.09)	 <0.0005		
Table	1.	Characteristics	of	CAIDE	population,	with	stratification	by	participation	in	re-examinations.			
For	continuous	variables.	values	are	means	(SD).	For	categorical	variables.	values	are	
percentages	within	each	of	the	four	participant	categories.	P-values	are	from	one-way	
ANOVA	a alysis		for	continuous	variables	and	from	chi2	for	categorical	variables.		
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In Study 1 and 2, we used mainly logistic regression to calculate the associations between the 
social and emotional predictor variables and the cognitive health outcome variables, 
including AD and MCI as specific outcomes.  
In Study 1, the main predictor variable was marital/cohabitant status in midlife. Participants 
were classified as cohabitants (living with a partners independent of formal marital status), 
single (never-married/cohabitant), divorced or widowed. In some calculations we also used 
marital status at follow-up for categorization of transitions in cohabitant status between 
midlife and follow-up, e.g. to identify participants who had been cohabitants at both 
occasions. We adjusted for several relevant health and life-style variables, including age, 
gender, education, smoking, physical activity, depressive feelings (feelings of hopelessness 
and loneliness), blood pressure, and cholesterol, all measured in midlife, and in addition for 
ApoE4 status, measured at follow-up in 1998. The main statistical method was logistic 
regression. 
In study 2, we used feelings of hopelessness at midlife as predictor, as measured through 
responses to the following statements: "I feel that it is impossible to reach the goals I would 
like to strive for" and "The future seems to me to be hopeless, and I can't believe that things 
are changing for the better". A five-point Likert scale was used, originally coded as 0 = 
absolutely agree; 1 = somewhat agree; 2 = cannot say; 3 = somewhat disagree; or 4 = 
absolutely disagree. In the data analysis we reversed the scores in order for higher scores to 
reflect a higher degree of hopelessness and summed them into a scale ranging from 0 - 8. In 
the first analysis this scale was entered as a five-level ordinal scale after collapsing categories 
with fewer than 10% of the observations (scores 0-1 and 5-8). To facilitate comparison with 
other studies, additional analyses were based on a median split dichotomization of the 
original hopelessness scale. The statistical analysis was of the same type as in Study 1. 
In Study 3, with access to a continuous data of time points for dementia diagnoses and dates 
of death, we used survival models to analyse the associations based on outcome data from 
linked registers. In this study we included participants also from the second follow-up in the 
CAIDE population, in addition to verified dementia diagnoses from registers, both on 
participants (N=1511) and non-participants (N=489) in the two re-examinations (see Table 
1). As we only had access to dementia as diagnosis, without subtypes, from the registers, we 
used any type of dementia as outcome in this study in order to compare and combine 
information from registers and re-examinations. We first performed a log rank Meyer-Kaplan 
survival analysis and censored all who died without a prior dementia diagnosis or who were 
alive at the end of Study. In the Cox regression survival analysis we also adjusted for several 
potential confounders with an association to both living and feeling alone and to dementia 
incidence, including age at baseline, gender, education, occupation, cholesterol and feelings 
of hopelessness. These analyses were performed by either using dementia diagnoses from the 
re-examinations  
For a more complete description of methods and participants, see the corresponding papers 1-
3.  
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5.2 STUDY 4 
This study was part of the Successful Ageing and Enrichment (SAGE) study, led by the 
Linnaeus University and Harvard Medical School, and with several collaborating institutions. 
Study 4 related to the aim of addressing biological mechanisms of possible relevance for 
associations of the type demonstrated in the previous three studies, and to the aim of 
complementing an epidemiological association study design approach with an experimental 
approach. In this study the participants were nineteen healthy volunteers aged averagely 70.8 
years, ranging from 66 to 78 years, eleven women and eight men, from a region in the Växjö 
city area, south Sweden. For further demographical information, see Table 2 (from paper 4). 
 
Table 2 Characteristics of participants in study 4. 
Numbers are mean values with SEM for continuous variables and % participants for the 
nominal variable (gender). 
 
We used an experimental within-subjects design to measure effects on BDNF levels in serum 
from three different activities that the participated performed during 35 minutes. The three 
activities were a/ aerobic physical exercise of moderate intensity, b/ a cognitive training 
session, and c/ a session of mindfulness. A specific sequence of conditions was randomly 
assigned to each participant to obtain a fully balanced design. The time interval between 
sessions was at least one week for each participant, and we kept the time of day as similar as 
possible within each person. In addition, all sessions were performed between 09 and 11 am 
for all participants. (For a schematic overview of this design, see Fig 11.)  
BDNF	responsivity	in	older	humans	
	
	 [Skriv	t xt]	 		 	
30	
 
 
Variables	
Mean	value	(±SEM)	
or	%	(N=19)	
Gender	(%	female)	 57.9	
Age	(years)	 70.8	±	0.8	
Formal	education	(years)	 8.02	± 1.24	
Continued	adult	education	(total	time	in	years)	 2.63	± 	0.23	
MMSE	score	(range	0-30)		 28.9	±	0.2	
Cognitive	performance	in	CogMed,	average	ratio	of	correct	answers		 0.72	±	0.01	
Physical	activities	in	daily	life.	Index	score	(range	0-40)		 19.1	±	1.2	
Systolic	blood	pressure	(mm	Hg,	average	of	three	measures)	 145	±	2.8	
Diastolic	blood	pressure	(mm	Hg,	average	of	three	measures)	 84	±	1.4	
Resting	pulse	(average	of	three	measures)	 75.8	±	0.8	
Self-rated	health	(1-4,	where	4	is	best	health)	 2.53	±	0.77	
Health	problems,	average	index	score	(0-1	on	35	symptoms)	 8.05	±	1.22	
 
Table 1 Characteristics of participants 
Numbers are mean values with SEM for continuous variables and % participants for the 
nominal v riable (gender).	
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Fig 11. Schematic illustration of the within-subjects experimental design in study 4. 
We collected 8 ml blood samples from a lower arm vein directly before each session started 
and at three time points (0, 20 and 60 minutes) after the conclusion of each session. The 
blood samples were kept at room temperature for 30 min to allow for clotting, and were then 
centrifuged at 2000 g for 10 min at 4°C to separate serum. The different samples were 
marked and frozen at -80 degrees C until analysis. We used an ELISA type of analysis to 
estimate levels of BDNF in the different serum samples after diluting them according to 
instructions from the manufacturer of the ELISA kit we used (Human BDNF Quantikine 
ELISA, DBD00, R&D Systems, Minneapolis, MN). 
To take statistical advantage of the within-subjects cross-over design, we used repeated 
measures ANOVA to estimate the difference in effects on BDNF levels from each activity 
within each subject. 
For a more complete description of the Methods we used in this study, see paper 4. 
This study was approved by the regional ethical review board in Linköping (decision dnr 
2013/154-31). 
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6 SUMMARY OF RESULTS 
In this summary some of the most salient results from each study have been selected and 
illustrated. For a detailed presentation of all results, see the corresponding papers that are 
included in this thesis. 
 
6.1 STUDY 1 
We found 285 individuals among the CAIDE participants who at midlife had been living 
without a partner. Compared to the 1147 cohabitants, they had approximately a two-fold risk 
of cognitive impairment (MCI or dementia) at follow-up, after full adjustment for potential 
confounders (OR 2.09, CI 1.3 – 3.4). For those who had lived alone both at midlife and in 
later-life, the corresponding odds ratio was 2.89 (CI 1.7 – 5.0).  The associations were similar 
in relation to each cognitive health outcome (any cognitive impairment, and separately to 
MCI and AD), as illustrated in Fig 12. 
 
Fig 12. Associations with any cognitive impairment, mild cognitive impairment (MCI) and 
AD for non-cohabitants (brown bars) both at baseline and follow-up in relation to cohabitants 
(blue bars).  
Stars indicate level of statistical significance (* ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0005) 
 
We also found that among non-cohabitants in midlife, the risk for widowed persons was 
higher than for any other category (single or divorced), compared to cohabitants. This 
difference was accentuated when we also stratified for ApoE4 carrier status, and especially 
when the outcome was Alzheimer’s disease, as compared to mild cognitive impairment 
(MCI). Fig 13 illustrates these associations when the risk for ex-cohabitants (widowed and 
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divorced) was compared to those who were cohabitants both in midlife and in later life, 
including stratification for ApoE4 status.  
 
 
Fig 13. Associations with mild cognitive impairment (MCI) and AD for three groups with 
respect to cohabitant status at midlife and in later life. stratified for ApoE4 status.  
Fully adjusted odds ratios in relation to cohabitants without ApoE4 (reference group). Stars 
indicate level of statistical significance (* ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0005) 
The separate odds ratio for those who were ex-cohabitants both in midlife and at follow-up 
and in addition carried the ApoE4 allele was a high 25.55 (5.7 - 114.5, P=<0.0005), in 
relation to the reference group (cohabitant non-ApoE4-carriers at both time points). 
 
6.2 STUDY 2 
We found higher levels of hopelessness in midlife, but not at follow-up, to be associated with 
cognitive impairment at follow-up; the adjusted odds ratio for each step of the five-level 
hopelessness scale was 1.30 (95% confidence interval 1.11-1.51, P = 0.001) for any cognitive 
impairment and 1.37 (95% 1.05-1.78, P = 0.020) specifically for Alzheimer’s disease. These 
associations remained significant also after the final adjustments for depressive feelings and 
for hopelessness at follow-up.  
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Also when measured at follow-up, feelings of hopelessness were significantly more 
pronounced among participants who were to be diagnosed as cognitively impaired, but this 
association was largely eradicated when adjustments were made, except for Alzheimer’s 
disease as separate outcome (OR 1.38, 95% confidence interval 1.00 – 1.90, P = 0.051). This 
association also became statistically non-significant after final adjustment for depressive 
feeling at the re-examination.  
We found no significant differences in scores of hopelessness between baseline and 
follow-up within any of the outcome groups, including within the cognitively healthy 
reference group. In other words, persons who in later life would be found with cognitive 
impairment, had higher levels of hopelessness, but this difference in hopelessness 
feelings between the groups existed already at midlife. The pattern of these results is 
illustrated in Fig. 14.  
 
 
 
Fig 14. Levels of hopelessness at baseline and follow-up, stratified by cognitive health status 
at follow-up.   
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When we stratified the participants into ApoE4 carriers and non-carriers, the association 
between midlife levels of hopelessness and cognitive impairment in later life was more 
pronounced among ApoE4 carriers, especially when Alzheimer’s disease was the outcome. 
With non-carriers with low levels of hopelessness at midlife as reference, this subgroup had 
an adjusted odds ratio of 8.08 (3.1-21.1). After final adjustment also for depressive feelings 
during the follow-up, the corresponding odds ratio was reduced to 6.48 (95% confidence 
interval 2.4-17.5, P = < 0.0005). 
 
6.3 STUDY 3 
We found that persons who lived alone and in addition felt lonely in midlife had a higher risk 
of a dementia diagnosis decades later compared to cohabitants, both to cohabitants who felt 
alone and especially to those who did not. Another consistent result in this population was the 
absence of a risk increase for persons who lived with a partner, but who felt lonely. These 
results were consistent whether the calculations were based on registered dementia diagnoses 
or if also data from the clinical diagnoses at the re-examinations were included in the 
analysis, and they were largely independent of potential confounding variables.  
The log rank Kaplan-Meyer analysis, based on incidence of verified dementia diagnoses in 
registers, showed a statistically significant overall difference in the survival distributions 
between the four groups, χ2(3) = 18.50, p < 0.0005 (Mantel-Cox log rank analysis). Pairwise 
comparisons (Mantel-Cox) showed that the risk of a dementia diagnosis after the baseline 
measurements was significantly shorter for persons who both lived alone and felt lonely, both 
in relation to cohabitants who did or did not feel lonely (χ2 = 6.86, p = 0.009, and χ2 = 11.71, p 
= 0.001, respectively), but not in relation to non-cohabitants without feelings of loneliness. 
The non-cohabitants without feelings of loneliness differed in relation to the two cohabitant 
groups (with and without feelings of loneliness), but to a weaker extent (χ2 = 9.54, p = 0.002 
and χ2 = 3.81, p = 0.051, respectively). Cohabitants who felt alone did not significantly differ 
from cohabitants without such feelings. The pattern of these results is illustrated in Fig. 15. 
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Fig 15. Survival functions for incidence of dementia among persons who lived and/or felt 
alone.  
From Kaplan-Meyer log rank analysis based on register data. 
 
Cox regression analyses with adjustments did not change this pattern and the hazard ratio 
(HR) for a dementia diagnosis for the group who in midlife had both lived alone and felt 
lonely was statistically significant in all models, also after adjustment for feelings o 
hopelessness at baseline (1.67, CI 1.06 – 2.61, P = 0.025 after full adjustments).  
When corresponding analyses were performed exclusively on the 1511 participants who 
participated in any or both re-examinations, the pattern of results was maintained, but 
statistical significance was lost. When re-examination data and registry data were combined, 
the results were almost identical to the calculation based only on registry data (HR 1.65, 95% 
CI 1.08 – 2.53, P = 0.022). When the calculations were stratified for gender, based on the 
combined information from both registers and re-examinations, the pattern was reproduced 
separately within each gender.  
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6.4 STUDY 4 
In this study we found a significant immediate increase in serum BDNF levels in healthy 
older individuals after a 35-minute physical exercise session, but not in the same individuals 
when they participated in either cognitive training or mindfulness practice for the same 
duration of time. The mean post-intervention BDNF level was 22.5 ± 0.99 ng/mL after the 
physical exercise session, compared to 19.2 ± 1.17 ng/mL at baseline (p = 0.004, paired t-test, 
Cohen’s d = 0.75). Figure 16 depicts these changes in BDNF levels from baseline in relation 
to each of the three post-intervention time points (at 0, 20 and 60 minutes), and in addition to 
the average of these three post-intervention measures. 
 
Fig 16. BDNF level changes from baseline after physical exercise, cognitive training and 
mindfulness practice. 
Bars represent the difference in ng/ml serum between baseline and each post-intervention 
time point, in addition to average change.  
 
We also found considerable individual variation in BDNF responses across the nineteen 
individuals. When we in post-hoc analyses explored possible sources behind this variation we 
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found a negative correlation with BDNF level at baseline and the degree to which BDNF 
levels increased during the intervention (rxy -0.49, p = 0.03), meaning that participants with 
higher baseline levels of BDNF tended to have a smaller BDNF response. We also found a 
significant correlation between working memory performance and post-intervention BDNF 
values (rs = 0.50, p = 0.03) after physical exercise, but not to basal levels or to degree of 
BDNF change in our participants (Table 3). When we, according to the hypothesis of a 
ceiling effect for the BDNF response, used tertiles to stratify participants according to their 
baseline BDNF values, we found a significant correlation with working memory performance 
also for BDNF change within the subgroup with the lowest baseline values (rsy = 0.89, p = 
0.02) – but still only in the physical exercise condition (Table 3).   
 
Table 3. Correlations between working memory performance and BDNF levels at baseline, 
BDNF level increases and BDNF post-intervention levels for the different interventions, 
stratified according to baseline BDNF levels. 
Numbers are coefficients from Spearman correlations with exact p-values beneath.  
The stratification of participants into lower versus higher baseline levels of BDNF was 
according to first and third tertiles.  
 
It should be pointed out that these correlations were based on only nineteen subjects, and 
even fewer after the stratification shown in the lower part of Table 3. Although the 
participants were the same across conditions, this means that the statistical strength of the 
cross over design does not fully apply to these calculations, in contrast to the main 
calculations. The pattern of results could therefore be of greater interest than any single 
association, i.e. that strong associations with working memory performance were all found in 
the single condition where we also showed a main effect from the intervention.  
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Intervention Physical exercise Cognitive training Mindfulness 
BDNF outcomes 
Baseline 
level 
Response  Post-interv 
level 
Baseline 
level 
Response  Post-interv 
level 
Baseline 
level 
Response  Post-interv 
level 
All participants (N=19) 0.25 
p = 0.31 
0.22 
p = 0.38 
0.50 
p = 0.03 
0.08 
p = 0.74 
0.09 
p = 0.72 
0.03 
p = 0.90 
-0.12 
p = 0.63 
-0-13 
p = 0.60 
-0.09 
p = 0.72 
Stratified	
by	
baseline	
BDNF		
Participants with 
lower levels (N=6) 
-0.60 
p = 0.21 
0.89 
p = 0.02 
0.71 
p = 0.11 
0.07 
p = 0.88 
0.36 
p = 0.43 
0.32 
p = 0.48 
-0.03 
p = 0.96 
-0.20 
p = 0.70 
-0.37 
p = 0.47 
Participants with 
higher levels (N=6) 
0.71 
p = 0.11 
0.31 
p = 0.54 
0.77 
p = 0.07 
0.26 
p = 0.63 
-.66 
p = 0.16 
-0.43 
p = 0.40 
0.26 
p = 0.62 
-0.37 
p = 0.47 
0.14 
p = 0.79 	
Table 3. Associations of working memory performance with BDNF levels at baseline, with BDNF response and with BDNF post-intervention 
levels for the different interventions, stratified according to baseline BDNF levels.  
All correlations were calculated between BDNF levels and the average maximum score on all CogMed items (see Methods). 
Numbers are coefficients from Spearman correlations with exact p-values beneath.  
The stratification of participants into lower versus higher baseline levels of BDNF was according to first and third tertiles.  
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7 DISCUSSION 
As the results from each of the four studies are separately discussed in paper 1-4, the main 
purpose of this chapter is to integrate the results from these studies and discuss their possible 
implications for cognitive health and possible underlying mechanisms.  
7.1 SOCIO-EMOTIONAL FACTORS 
7.1.1 Cohabitants and non-cohabitants 
Study 2-4 emanated from the results of the first study and the questions they raised. In that 
study we showed that living without a partner at midlife was associated with approximately a 
doubled risk in later life of being diagnosed with mild cognitive impairment or dementia, 
averagely twenty years later. When we compared persons who had been living alone both at 
midlife and in later life with cohabitants at both time points, the associations were even 
stronger. The credibility of these results was strengthened by the similar associations we 
found for mild cognitive impairment and Alzheimer’s disease as independent outcomes. 
Another important feature in these results were the differences within the non-cohabitant 
group, with a marked risk increase for widowed persons as compared to singles, defined as 
persons who had never been married or lived with a partner. Previous studies that found a risk 
increase from living alone[152,153]had interpreted the association as a possible effect of less 
cognitive stimulation from living alone, i.e. an interpretation related to the brain reserve 
hypothesis[104]. We could not exclude this as a possible explanation, especially for the risk 
increase for the non-cohabitant group as a whole. But the largest contribution to the risk 
increase among non-cohabitants did not come from the singles, but from the widowed, i.e. 
from participants who in most cases had been cohabitants for a substantial portion of their 
lives. At least in a life-course perspective, this did not seem to support the brain reserve 
hypothesis as a full explanation for the cohabitant advantage. Could the emotional 
consequences of losing a partner be an alternative or additional explanation to account for the 
increased risk we saw especially for the widowed group? Other studies have shown that 
negative feelings, e.g. global depressive feelings, feelings of hopelessness and feelings of 
loneliness had been found to increase the risk of mortality [154-156], morbidity [154,157-
159] and also specifically cognitive impairment in later life [121,160-170]. Thus, did the risk 
increase we saw reflect the emotional consequences of being widowed already in midlife? 
7.1.2 Feelings of hopelessness 
When we consulted the CAIDE database we found that feelings of hopelessness had been 
measured at both midlife and follow-up by two questions. In addition, the same two questions 
had been used in at least three other studies that found an increased risk of mortality and 
carotid atherosclerosis [171], and they had also been found as a better predictor in these 
regards than global depression [172]. Others have suggested that hopelessness may be a 
central dimension in depression of equal or greater relevance than global depression for 
health and mortality [157] [173], including risk of suicide [174].  
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When we compared levels of hopelessness between widowed and non-widowed, we found 
that such feelings were indeed more common in the widowed group (unpublished results), but 
we also saw that such feelings were not uncommon among other participants, independent of 
cohabitant status. This observation was also in line with an epidemiological study that later 
reported a relatively high prevalence of hopelessness feelings in Eastern Finland from where 
our population had been sampled [175]. When we calculated the associations between 
feelings of hopelessness at baseline and cognitive health at follow-up, it confirmed our 
hypothesis that hopelessness increased the risk of dementia independently of being widowed 
or not.  
As hopelessness was measured in exactly the same way both at baseline and during follow-up 
it also gave us a unique opportunity to investigate whether such depressive feelings reflect a 
prodromal or a causal relation with cognitive impairment. Many studies report that depression 
is a common dementia comorbidity [176,177], and that the two conditions in addition may be 
mechanistically linked[178]. But very few studies have actually followed individuals over a 
sufficiently long period of time to substantiate the claim that depression is a prodromal 
symptom of dementia. One of the few research groups that studied development of 
depression during the prodromal phase, did not find depressive feeling to increase at all 
[170], and in another population “not noticeable” so [179]. Compared to our study, we had a 
considerably longer follow-up time (averagely 21 years, compared to 11 and 8-9 years in 
these other studies). The long pre-clinical phase before a dementia diagnosis would in that 
sense put us in an even better position to address the causality versus prodromal hypotheses.  
In our study we found that persons with a dementia diagnosis had higher levels of 
hopelessness feelings at the time they were diagnosed, compared to persons who were 
cognitively healthy at follow-up, consistent with depression as a prodromal symptom. But 
when we traced the same persons back to when they were only in midlife, we found the same 
difference already then, and with no noticeable increases between the two time points. (From 
Figure 14, an increase can be seen only among persons who later would develop Alzheimer’s 
disease, but also this difference was not close to being statistically significant.) In summary, 
these findings should add to the credibility that depressive feelings are somehow implicated 
in the causal mechanisms, rather than only a prodromal symptom, in the development of both 
mild cognitive impairment and Alzheimer’s disease.  
Compared to the studies by Wilson et al[170] [179], we had not screened the participants for 
dementia or measured cognitive performance at baseline. With participants only in midlife 
and a mean survival time of averagely only 4-5 years[79], we could at least exclude the 
possibility that any of them would have had early clinical dementia averagely twenty years 
prior to follow-up. But we could not with certainty exclude the possibility that some of them 
had been in an early pre-clinical phase already at baseline, especially for those with a shorter 
follow-up time than average. In that case, the association we found could still reflect reverse 
causation, at least to some degree. We tested this possibility by dividing the persons in a 
younger (35-50 years) and an older (50+) subgroup from baseline. When we calculated the 
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associations separately for these groups, we found no support for this possibility. On the 
contrary, the association was somewhat stronger for those who were only between 35-50 
years at baseline. 
7.1.3 Feelings of loneliness and cohabitant status 
The fact that feelings of hopelessness were common also among non-widowed participants 
and the fact that we had adjusted the original associations between cohabitant status and 
dementia also for feelings of hopelessness, suggest the involvement of other factors behind 
this association. In addition we did also see a risk increase for other non-cohabitant 
subgroups. If emotions can have a long-term impact on cognitive health, feelings of 
loneliness seemed a natural candidate behind a risk increase for persons who live alone. It 
seemed also possible that such feelings could have been more pronounced after losing a 
partner than for persons who were singles, which could contribute to the elevated risk for this 
non-cohabitant subgroup. Similar to feelings of hopelessness, feelings of loneliness had in 
other studies been found to increase the risk of mortality[180], morbidity[181] and 
dementia[121]. In line with previous studies [182] we noticed that feelings of loneliness were 
not exclusively found in persons who lived alone. From a statistical point of view this was 
also a necessary condition in order to separate their long-term associations, if any, with 
cognitive health in later life. In an attempt to achieve this aim, we collapsed the three non-
cohabitant categories (divorced, widowed and singles) in order to use the same dichotomous 
cohabitant – non-cohabitant variable we had used in the first study. Participants were also 
categorized into two groups of relatively higher or lower levels of loneliness feelings, as 
described in the Methods section. By combining these two dichotomous variables we could 
categorize the participants into four groups (cohabitants and non-cohabitants with high or low 
levels of loneliness) and relate to the dichotomous outcome of either having a subsequent 
dementia diagnosis or not. The results indicated a more complicated association to the risk of 
a dementia diagnosis than we had expected. While the combined status of living alone and 
feeling alone had a consistent and robust association with the risk of a subsequent dementia 
diagnosis, indicating an additive relationship between the objective and subjective aspects of 
alone-ness, there was no indication that feeling lonely increased dementia – if the participant 
lived had lived with a partner at baseline. Expressed in other terms; living with a partner 
seemed to protect against the otherwise adverse health effects of feeling alone. Although 
statistical significance was only consistently found for non-cohabitants who in addition felt 
lonely in relation to the reference group, the same pattern re-emerged whether we based the 
analyses on register data, on clinical evaluations during the re-examinations, or when we 
combined the two sources of information. The unadjusted log rank Kaplan-Meyer analysis 
and the Cox regression also gave a very similar picture, and the pattern was not dramatically 
affected by adjustments for different potential confounders. The same pattern was also 
repeated when we made separate analyses on men and women.  
Some of these results may seem counter-intuitive. Why was there an increased dementia risk 
from living alone if these persons did not also feel lonely? Although many studies report that 
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living alone, social isolation and feelings of loneliness all contribute to increased mortality 
[180], few studies have attempted to directly investigate how the two are related. One study 
investigated mortality risk over seven years with a similar aim as ours to investigate the 
relation between social isolation, measured through contact with family and friends and social 
participation, and feelings of loneliness [156]. Both variables predicted mortality separately, 
but the association with social isolation was more robust and remained also after adjustment 
for loneliness, while loneliness did not when social isolation and other factors were was 
adjusted for. Despite the differences between the studies, in follow-up time, the predictor 
(social isolation versus living alone) and the outcomes (dementia versus mortality), being 
alone emerged as the strongest predictor in both studies. This is in contrast to a study by 
Wilson et al [121], who found that feelings of loneliness increased the risk of Alzheimer’s 
disease, also after adjustment for social isolation.  
The focus in our study was on living alone, rather than social network size or number of 
friends. In a recent meta-analysis on social relationships and dementia risk, Kuiper et al [120] 
concluded that the element of social interaction, rather than network size, was the most 
relevant aspect in social relationships and the relation with cognitive health. One meta-
analysis that compared associations with mortality from living alone and the size of social 
networks/social isolation as separate dimensions, also found that living alone had a somewhat 
stronger association [180].  
7.2 THE RELEVANCE OF GENERAL HEALTH MECHANISM FOR AD 
 In a wider context, it may seem surprising, or even suspicious, that not only living alone, the 
loss of a partner, and feelings of hopelessness and loneliness, i.e. factors in focus of this 
thesis, but a host of other factors, including depression, stress, high blood pressure in midlife, 
high cholesterol, and low level of physical activity, have all been reported to increase the risk 
of Alzheimer’s disease and other types of dementia. As mentioned in the chapter 3.3.7, not 
only are many of these factors associated with Alzheimer’s disease and other types of 
dementia, but to many other diseases as well. This seems to indicate the existence of a 
common mechanism for several diseases that could also be relevant for the risk of 
Alzheimer’s disease and other types of dementia. In that chapter I proposed that the immune 
system could be involved in such a mechanism; when weakened or dysfunctional, whether 
due to stress, depression, an already existing disease, long-term sleep deprivation, toxic 
exposures, frailty due to high age, or any other reason, the risk should increase for various ill 
health conditions to develop, due to immunological dysfunction and inefficiency [183]. The 
specific disease that will result in such a scenario would then, according to this hypothesis, be 
determined by specific vulnerabilities, where genetic factors could have an important role. A 
proper analogy to illustrate this hypothesis of general disease proneness leading to a specific 
disease, as determined by specific vulnerabilities, could be that of a chain, with some links 
stronger, others weaker. When under pressure, the chain will naturally break where the 
weakest link is. For a person with a genetic disposition to develop AD, that disease could be 
the more probable specific disease outcome. We found indirect support for this hypothesis 
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when we stratified persons according to ApoE4 status and whether they had been exposed to 
either the loss of a partner (Study 1) or feelings of hopelessness (Study 2). In both studies, 
and especially in Study 1, the ApoE4/risk factor combination lead to a dramatic risk increase 
for specifically AD, rather than mild cognitive impairment. A similar magnification effect of 
carrying the ApoE4 allele together with different non-genetic risk factors has also been 
reported by others[70]. One way to test this hypothesis further could be to investigate if also 
genetic vulnerabilities for other diseases magnify the risk of the associated disease, when 
such vulnerabilities are combined with factors that seem to magnify the risk of AD in ApoE4 
carriers, especially factors that are known to impair immunological efficiency.  Depressive 
feelings, traumatic experiences, extensive sleep problems, and chronic stress are factors with 
well-known immunological effects[114,116,117,139] that could be of special interest to 
investigate further with such an aim.  
Although the immune system has developed through evolution over millions of years to the 
present level of perfection, it is common in AD research to focus on the other side of the coin, 
if immunological implications in AD are at all considered, namely on the effect of 
inflammation as a possible causal mechanism in AD – or even the idea that AD could be an 
auto-immune disease [184]. Inflammation is the common process through which the immune 
system attacks antigens and accomplishes repair after injury, in other words, accomplishes 
the task it is designed for. The idea that inflammation could have a causal role for the 
development of AD has probably been nourished by the fact that amyloid β accumulation has 
been observed as a precursor to clinical AD, and that inflammation and amyloid load have 
been found to coexist[185]. New findings, indicating that amyloid β could have antimicrobial 
properties, and could be even part of the innate immune system [82], could, in addition to 
other sources of doubt concerning the role of amyloid β[83] [81] [84], lead to a drastic re-
interpretation of why inflammation and accumulation of beta-amyloids co-exist; that they 
both represent an immunological attempt to counteract continued development of an 
Alzheimer’s disease process, probably in early phases of the disease. This interpretation is 
also consistent with the observation that many persons with large amounts of amyloid 
plaques have no other signs of AD or other cognitive impairments[81]. With an alternative 
interpretation, amyloid plaques in cognitively healthy persons may be remnants from 
previous successful attempts to stop the disease from developing further, as has also been 
suggested by others[186,187]. Taken together, these findings could justify a shift of focus 
into regarding the normal role of the immune system; to fix health problems, not to create 
them, as an alternative way to relate immunological function and Alzheimer’s disease. From 
such an alternative perspective, development of clinical AD could reflect immunological 
inefficiency to accomplish this task, either due to factors that have weakened the immune 
system or in situations when the genetic odds are too overwhelming. The factors studied in 
this dissertation are closely related to factors that according to previous studies can cause 
immunological imbalances and inefficiency, such as grief, depression and chronic stress 
[116]. Such an effect on immunological functioning may be the reason why social and 
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emotional factors can affect the risk of Alzheimer’s disease, especially when a presence of 
AoE4 makes the person more vulnerable to develop this specific disease.  
7.3 BDNF: PART OF A SPECIFIC MECHANISM BEHIND ALZHEIMER’S 
DISEASE? 
Even if such a broad general heath mechanism has relevance also for Alzheimer’s disease on 
a macro level, it still contributes little to understand the specific mechanisms behind the 
initiation and development of the disease at the micro level. One of the core symptoms in 
AD, and possibly also in other neuropathological diseases [87], is synaptic dysfunction and 
loss [188]. Some studies have reported that toxic amyloid β oligomers may be 
responsible[189], but as neurotrophic factors are critically involved in synaptic repair and 
synaptogenesis[97], and as decreased BDNF expression has been found in brains of persons 
with AD[95], BDNF functionality could also be of interest as a possible key to better 
understand this disease. BDNF is of central importance for brain plasticity, where BDNF 
plays a key role, but plasticity is severely reduced or eliminated with Alzheimer’s disease. 
Based on this, Lu et al[188] have even suggested that BDNF-based therapies against AD and 
other neuropathological conditions should be developed.  
The fourth study is based on the assumption that BDNF functionality is relevant for cognitive 
health and dementia. It aimed to investigate the immediate effects on BDNF levels from 
different types of activities in healthy elderly persons. In spite of the theoretical relevance of 
BDNF for cognitive health, and the urgent priority to counteract cognitive decline in old age 
in an ageing world population, we were surprised that no one seemed to have performed a 
study of this kind before. We found that 35 minutes of physical activity increased BDNF 
levels on average 25%, but found no such effects from the other activities, cognitive training 
or mindfulness. In previous studies it had been assumed that increased BDNF levels in serum 
after physical exercise reflects increased BDNF levels in the brain. The pattern of our results 
led us to conclude that the immediate BDNF increases in serum from this exercise instead 
had a peripheral, not a CNS origin. In spite of its name (brain-derived neurotrophic factor), 
BDNF can be produced in a range of cells outside the nervous system, including in immune 
cells, in the kidney, in neuromuscular joints, and in salivary glands[190-192]. In addition, 
some studies have reported that brain BDNF does not pass the blood-brain-barrier (BBB) 
[193], that BDNF increases in the brain are not reflected in blood[194], or at least that the 
efflux from the brain into the blood stream is relatively slow[195]. It also seemed counter-
intuitive, considering the role of BDNF for healthy brain functioning, that physical activity 
would stimulate the brain to produce BDNF to a higher extent than a cognitively demanding 
task would.  
Another finding was that the variation we saw between individuals in the BDNF responses 
they had, and especially the levels after physical exercise, correlated with individual 
differences in working memory performance. As a high level of cognitive function should 
require good BDNF functionality in the brain, these two findings in combination could mean 
that BDNF functionality in one part of the body is a marker for the ability to produce BDNF 
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also in other parts, e.g. in the brain. This speculation, based on a correlation only among 18 
individuals, of a systemic component needs to be further investigated. If the speculation is 
correct, and if the finding of a relatively slow BDNF efflux from the brain is correct[195], it 
should mean that an intervention over weeks and months could show that BDNF effects from 
cognitive training are also reflected in elevated BDNF levels in serum. As BDNF is central 
for brain plasticity, and if synaptic dysfunction and loss is an early event in AD, a dramatic 
consequence of this proposed hypothesis is that BDNF responsivity in serum after physical 
exercise could be marker of brain health, and possibly also an early marker of AD. The 
hypothesis could also be tested by investigating if persons who gain relatively more, in terms 
of cognitive performance improvements, also show a parallel response in terms of BDNF 
levels during the intervention period. 
In conclusion, this study raised more questions than it answered and some of the results were 
unexpected. It scratched the surface of a possibly relevant micro level mechanism behind AD 
development and generated many ideas for future studies.  
7.4 CONCLUSIONS 
To live with someone may be beneficial for cognitive health in a long-tem perspective and 
feelings of loneliness can dramatically increase the risk of dementia if persons who feel 
lonely also live alone. To live alone after having lost a partner was associated with a unique 
risk increase, as compared to having always lived without a partner. Hopelessness, a central 
emotional dimension in depression, was also associated with a higher dementia risk. The fact 
that not only social and emotional factors can increase the risk of dementia, but a host of 
other factors, and that many of these are also related to other bad health outcomes, could 
indicate a general systemic effect that results in specific diseases as a result of specific 
vulnerabilities where genetic dispositions could play a role. The dramatic risk increase we 
found when ApoE4 status was related to social and emotional factors in two of the studies 
seems to support the relevance of such a general health mechanism also for Alzheimer’s 
disease. On the micro level, BDNF functionality seems as a promising field to generate and 
test new hypothesis concerning early dementia development, early detection and potentially 
also to discover new therapeutic interventions. 
Medical research usually has a focus on disease and disease-related factors. If loneliness, 
living alone and depressive feelings imply increased dementia risk, the other side of the coin 
should mean that close relations and interactions, and positive feelings promote cognitive 
health. 
7.5 FUTURE DIRECTIONS 
One of the factors I have only touched upon in this thesis, is sleep. Sleep is of critical 
importance for immunological efficiency, and both sleep deprivation and poor sleep quality 
are associated with increased risk of mortality and a range of health disorders [114]. If the 
common and non-specific health mechanism proposed here, with the immune system as a 
suggested key agent, is indeed relevant also for the development of Alzheimer’s disease and 
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other dementias, sleep quality should show a long-term association with cognitive health in 
later life. Although many cross-sectional studies exist that describe sleep disorders in persons 
who have dementia, no well-designed prospective studies with sufficient follow-up time were 
found. Such studies could be of value to understand and prevent dementia, and also 
contribute to evaluate the role of immune function for dementia development.  
Participant bias may be seriously underestimated as a source of error in prospective 
population studies. The common procedure to describe baseline differences, if such data are 
at all available, between participants and non-participants, is, based on the results in Study 3, 
clearly insufficient to account for this. Linkage of registers with careful verification of 
diagnoses, or other outcome variables of interest, would probably dramatically increase the 
validity of results from prospective cohort studies. 
Inconsistent evidence and therapeutic failures could mean that amyloid-based theories on the 
causal mechanisms behind AD need to be revised and/or that other mechanisms may be more 
relevant. The role of neurotrophic factors for synaptic dysfunction and loss of synapses in 
Alzheimer’s disease should be explored further with the aim to find new mechanisms of 
relevance for understanding and possibly also develop therapeutic strategies against AD and 
other dementias.  
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